Polycystic Ovary Syndrome · Web of Medicine

On this page

Quick Reference

RxDrug of choiceLetrozole 2.5-7.5 mg daily for ovulation induction; combined oral contraceptives (low-dose EE 20-35 mcg) for cycle control and hyperandrogenism.

AltAlternativesClomiphene 50-150 mg/day for ovulation induction; metformin 1500-2000 mg/day for metabolic dysfunction; GLP-1 RAs (liraglutide, semaglutide) for weight loss; spironolactone 50-100 mg BID for hirsutism.

⊘AvoidValproate (increases PCOS risk); high-dose estrogen COCPs in women with cardiovascular risk factors; non-dihydropyridine CCBs not relevant but avoid if heart failure present.

DxTest of choiceTransvaginal ultrasound with high-frequency probe for PCOM; 75-g OGTT for glucose tolerance; 17-OHP with ACTH stimulation to exclude NCAH.

ScKey scoreRotterdam criteria (2 of 3: hyperandrogenism, ovulatory dysfunction, PCOM); modified Ferriman-Gallwey score for hirsutism; STOP-Bang for sleep apnea screening.

→When to referEndocrinology for NCAH or complex metabolic cases; reproductive endocrinology for infertility; bariatric surgery for BMI ≥35 kg/m² after lifestyle failure; mental health for depression/anxiety.

PCOS is a chronic condition requiring multidisciplinary, phenotype-driven management with emphasis on lifestyle, appropriate pharmacotherapy for reproductive and metabolic goals, and long-term surveillance for cardiometabolic and psychiatric comorbidities.

Polycystic ovary syndrome (PCOS) is a common endocrine disorder affecting 5-18% of reproductive-age women, characterized by hyperandrogenism, ovulatory dysfunction, and polycystic ovarian morphology. It is the leading cause of anovulatory infertility and carries substantial metabolic and cardiovascular risks, including a 2-3 fold increased risk of type 2 diabetes and a 1.3-fold increased all-cause mortality. Diagnosis follows the Rotterdam criteria after excluding other causes. Management is phenotype-driven: lifestyle intervention, combined oral contraceptives for cycle control and hyperandrogenism, letrozole for ovulation induction, metformin for metabolic dysfunction, and bariatric surgery for severe obesity. Long-term surveillance for type 2 diabetes, cardiovascular disease, NAFLD, and mental health disorders is essential.

Overview and Recommendations

Background

•PCOS is a common endocrine disorder affecting 5-18% of reproductive-age women, defined by the 2003 Rotterdam criteria requiring at least two of three features: hyperandrogenism (clinical or biochemical), ovulatory dysfunction, and polycystic ovarian morphology (PCOM) on ultrasound. It is the leading cause of anovulatory infertility and carries a 2.3- to 2.5-fold increased risk of major adverse cardiovascular events by age 35.
•The condition is characterized by a self-reinforcing triangle of neuroendocrine dysregulation (elevated LH pulse frequency due to reduced hypothalamic sensitivity to progesterone), insulin resistance (present in 50-70% of women, independent of obesity), and ovarian hyperandrogenism. Insulin acts as a co-gonadotropin, upregulating ovarian CYP17A1 and suppressing hepatic SHBG, leading to elevated free testosterone.
•Four phenotypes exist under Rotterdam: A (classic, hyperandrogenism + ovulatory dysfunction + PCOM, highest metabolic risk), B (hyperandrogenic anovulation without PCOM), C (ovulatory PCOS, hyperandrogenism + PCOM), and D (normoandrogenic PCOS, ovulatory dysfunction + PCOM, most controversial). The Androgen Excess Society requires hyperandrogenism for diagnosis, excluding phenotype D.
•The 2023 International Evidence-Based Guideline retains Rotterdam criteria and recommends using population-specific cut-offs for PCOM (follicle number per ovary ≥20, ovarian volume ≥10 mL) and modified Ferriman-Gallwey score for hirsutism. In adolescents, diagnosis requires both hyperandrogenism and irregular cycles; PCOM is not used due to poor specificity during normal puberty.
•PCOS is associated with significant long-term risks: 3- to 7-fold higher risk of type 2 diabetes, pooled relative risk of 3.46 for endometrial cancer (due to unopposed estrogen from anovulation), and a high prevalence of depression (37%) and anxiety (48%). The disorder also predisposes to NAFLD, obstructive sleep apnea, and adverse pregnancy outcomes including gestational diabetes and preeclampsia.

Evaluation

•Suspect PCOS in any reproductive-age woman presenting with oligomenorrhea (fewer than eight cycles per year), hirsutism, acne, or infertility. Ask about age of menarche, menstrual pattern, weight gain, family history of PCOS or diabetes, and symptoms of hyperandrogenism.
•Examine for hirsutism using the modified Ferriman-Gallwey (mFG) score; a score ≥4-6 is abnormal depending on ethnicity. Look for acne, seborrhea, acanthosis nigricans (sign of insulin resistance), and measure BMI and waist circumference (≥88 cm in Caucasian women, ≥80 cm in Asian women).
•Order biochemical assessment: total testosterone, free testosterone (or calculated free androgen index), SHBG, androstenedione, DHEAS. Use LC-MS/MS for accurate measurement. Also measure 17-hydroxyprogesterone (17-OHP) to exclude non-classic congenital adrenal hyperplasia (NCAH); if >6 nmol/L (≈2 ng/mL), perform an ACTH stimulation test (250 μg cosyntropin, 17-OHP at 60 min; >10 ng/mL is diagnostic for NCAH).
•Exclude alternative causes: thyroid dysfunction (TSH), hyperprolactinemia (prolactin), Cushing syndrome (if clinical suspicion with 24-h urine cortisol, overnight dexamethasone suppression test, or late-night salivary cortisol), and androgen-secreting tumors (if total testosterone >5 nmol/L or rapid virilization, order ovarian/adrenal imaging).
•Perform a 75-g oral glucose tolerance test (OGTT) at diagnosis to screen for impaired glucose tolerance or type 2 diabetes, even if fasting glucose is normal. Repeat every 1-3 years based on risk.
•Order transvaginal ultrasound with a high-frequency probe (≥8 MHz) to assess for PCOM: follicle number per ovary (FNPO) ≥20 and/or ovarian volume ≥10 mL in either ovary. Anti-Müllerian hormone (AMH) is a surrogate marker (proposed cutoff 3.5-5 ng/mL) but not yet a formal diagnostic criterion due to inter-assay variability.
•Diagnostic criteria for adults: presence of at least two of three features (hyperandrogenism, irregular cycles, PCOM/AMH) after excluding other causes. For adolescents: both hyperandrogenism and irregular cycles required; PCOM excluded.
•Classify into phenotype: A (HA+OD+PCOM), B (HA+OD), C (HA+PCOM), D (OD+PCOM). This stratifies metabolic and reproductive risk and guides management intensity.
•Consider referral to endocrinology if NCAH is confirmed, or to reproductive endocrinology for infertility evaluation. Also consider sleep studies if obstructive sleep apnea is suspected (STOP-Bang score).

Management

•Initiate lifestyle intervention as the foundation: structured dietary modification, physical activity (aerobic exercise best for BMI reduction, combined aerobic+resistance for insulin resistance, mind-body exercise for glucose), and behavioral strategies. Aim for 5-10% weight loss, which reduces insulin resistance, lowers androgens, and restores ovulation in 30-50% of women.
•For menstrual regularity and suppression of hyperandrogenism (hirsutism, acne), prescribe combined oral contraceptives (COCP) as first-line: low-dose ethinyl estradiol (20-35 mcg) with a progestin (e.g., drospirenone, cyproterone acetate). Use for women not seeking pregnancy and without contraindications. Fourth-generation progestins offer additional antiandrogenic benefit but higher VTE risk.
•For metabolic dysfunction (insulin resistance, prediabetes, type 2 diabetes), use metformin 1500-2000 mg/day (start 500 mg BID, titrate to 850-1000 mg BID). Metformin improves menstrual cyclicity, reduces fasting insulin, and may improve live birth rates (OR 1.59 vs placebo) but is less effective for hirsutism. Monitor renal function and vitamin B12 annually.
•For ovulation induction in women desiring pregnancy, use letrozole 2.5-7.5 mg daily for 5 days starting cycle day 3-5. Letrozole is superior to clomiphene (live birth rate 27.5% vs 19.1%, NNT=12) with higher cumulative ovulation rates (61.7% vs 48.3%) and no increase in multiple pregnancy. Clomiphene 50-150 mg/day is second-line.
•For women with obesity (BMI ≥35 kg/m²) and PCOS, consider bariatric surgery (sleeve gastrectomy) after lifestyle failure. Surgery achieves 78% remission of PCOS vs 15% with medical therapy, and increases spontaneous ovulation 2.5-fold (BAMBINI trial). Remission is predicted by achieving final BMI <26-27.5 kg/m².
•For adjunctive weight loss in obese PCOS, consider GLP-1 receptor agonists (e.g., liraglutide 1.2 mg daily, semaglutide 1.0 mg weekly). They reduce BMI by ~1.4 kg/m² and improve metabolic parameters, but may cause lean mass loss (~28% of weight loss). Use off-label; monitor for gastrointestinal side effects.
•For IVF, use frozen-embryo transfer rather than fresh: higher live birth rate (49.3% vs 42.0%, NNT=14) and lower ovarian hyperstimulation syndrome (1.3% vs 7.1%, NNT=17). Monitor for preeclampsia (4.4% vs 1.4%, NNH=33).
•During pregnancy, consider metformin 500-1000 mg BID to reduce late miscarriage and preterm birth (PregMet2 trial: OR 0.50, 95% CI 0.22-1.08, pooled analysis significant). Metformin is safe during breastfeeding and does not increase congenital malformations.
•Monitor for endometrial hyperplasia in women with prolonged amenorrhea (>3-4 months) or abnormal uterine bleeding; perform transvaginal ultrasound or endometrial biopsy. Do not screen asymptomatic women routinely.
•Screen for depression and anxiety using PHQ-9 and GAD-7 at diagnosis and annually; refer to mental health services as needed. Prevalence of depression is 37%, anxiety 48%.
•Titrate therapy to targets: regular menstrual cycles (21-35 days), free androgen index <5, fasting glucose <100 mg/dL, HbA1c <5.7%, blood pressure <130/80 mmHg, LDL-C <130 mg/dL.
•For hirsutism not responding to COCP, add antiandrogens like spironolactone 50-100 mg BID (off-label; use with effective contraception due to teratogenicity). Consider eflornithine cream for facial hirsutism.
•Avoid valproate in women of reproductive age as it increases PCOS risk (HR 7.08 for >365 DDDs). Avoid high-dose estrogen COCPs in women with cardiovascular risk factors.
•Refer to bariatric surgery if BMI ≥35 kg/m² and lifestyle/metformin fail. Refer to reproductive endocrinology if ovulation induction with letrozole fails after 6 cycles.

Board Review — High Yield

•Rotterdam criteria, requires 2 of 3: hyperandrogenism, ovulatory dysfunction, polycystic ovarian morphology. Exclude other causes.
•Letrozole first-line for ovulation induction, superior to clomiphene (live birth 27.5% vs 19.1%, NNT=12).
•Phenotype A (hyperandrogenism + anovulation + PCOM) has highest metabolic and cardiovascular risk.
•Non-classic CAH must be excluded with 17-OHP; if >6 nmol/L, do ACTH stimulation test.
•Metformin improves menstrual cyclicity and reduces diabetes risk but does not improve hirsutism.
•Bariatric surgery achieves 78% remission in obese PCOS (BMI ≥35 kg/m²).
•Frozen embryo transfer preferred in IVF to reduce OHSS (1.3% vs 7.1%) and improve live birth.
•Depression and anxiety affect 37% and 48% of women with PCOS, screen routinely.
•GLP-1 receptor agonists are emerging for weight loss but cause lean mass loss.
•Premature adrenarche is a forerunner of PCOS, higher fasting insulin in affected girls.

Deep Dive — Evidence Details

Definition, Classification and Axis Nomenclature

▸PCOS is defined by the Rotterdam criteria requiring two of three: hyperandrogenism, oligo-anovulation, polycystic ovaries.
▸Four phenotypes (A-D) exist; phenotype D (normoandrogenic) is controversial and may not represent true PCOS.
▸PCOS confers a 2.3- to 2.5-fold increased risk of MACE and is a leading cause of anovulatory infertility.

HY High Yield: Phenotype B (hyperandrogenic anovulation without PCOM) carries the highest CVD risk, HR 2.47 for MACE [8].

Dx Diagnostic Essentials: PCOS is a diagnosis of exclusion; always rule out thyroid dysfunction, hyperprolactinemia, nonclassic congenital adrenal hyperplasia, and androgen-secreting tumors before applying criteria.

Polyendocrine metabolic ovarian syndrome (PMOS), previously called polycystic ovary syndrome (PCOS), is the most common hormonal disorder in women of reproductive age. — Polyendocrine metabolic ovarian syndrome — Polyendocrine metabolic ovarian syndrome (PMOS), previously called polycystic ovary syndrome (PCOS), is the most common hormonal disorder in women of ...Wikipedia ↗

Polycystic ovary syndrome (PCOS) is a common endocrine disorder of reproductive-age women defined by hyperandrogenism, ovulatory dysfunction, and polycystic ovarian morphology, with significant metabolic and reproductive implications ^[13]^D5.

Also Called / Synonyms

PCOS, Stein-Leventhal syndrome, polycystic ovary syndrome
Polyendocrine metabolic ovarian syndrome (PMOS), proposed 2026 global consensus name change ^[14]^D5
Hyperandrogenic anovulation, functional ovarian hyperandrogenism

Classification by Phenotype

The 2003 Rotterdam criteria, endorsed by the 2023 International Evidence-Based Guideline, require at least two of three features: (i) clinical or biochemical hyperandrogenism, (ii) oligo- or anovulation, (iii) polycystic ovarian morphology (PCOM) on ultrasound, after exclusion of other causes ^[2]^A1c^[9]^A1c^[13]^D5. This yields four phenotypes:

Phenotype	Hyperandrogenism	Ovulatory Dysfunction	PCOM	Notes
A (classic)	Yes	Yes	Yes	Most severe reproductive and metabolic phenotype ^[23]^D5
B (hyperandrogenic anovulation)	Yes	Yes	No	Also called NIH criteria; higher CVD risk (HR 2.47) ^[8]^B2b
C (ovulatory PCOS)	Yes	No	Yes	Mildest metabolic profile; often presents with hirsutism
D (normoandrogenic PCOS)	No	Yes	Yes	Most controversial; AES considers hyperandrogenism essential ^[1]^A1c

The Androgen Excess Society (AES) 2006 criteria require hyperandrogenism plus one of anovulation or PCOM, excluding phenotype D ^[1]^A1c. The 2023 International Guideline retains Rotterdam but recommends using population-specific cut-offs for PCOM and mFG score ^[2]^A1c^[9]^A1c. In adolescents, diagnosis requires both hyperandrogenism and irregular cycles; PCOM is not used due to poor specificity ^[21]^D5.

Clinical Significance

PCOS affects 5-18% of women worldwide and is the leading cause of anovulatory infertility ^[13]^D5. It carries a 2.3- to 2.5-fold increased risk of major adverse cardiovascular events (MACE) by age 35 ^[8]^B2b, a 3- to 7-fold higher risk of type 2 diabetes, and significant psychological burden including body image dissatisfaction ^[7]^A1a. Bone health is also affected, lean women with PCOS (BMI <27 kg/m²) have lower vertebral bone density, while those with BMI ≥27 kg/m² have increased bone density ^[5]^A1a.

Controversies and Guideline Disagreement

Question	Position A	Position B	Strength	Implication
Diagnostic criteria	Rotterdam 2003 (any 2 of 3) ^[2]^A1c^[9]^A1c	AES 2006 (requires hyperandrogenism) ^[1]^A1c	Rotterdam supported by 2023 guideline; AES minority view	Phenotype D may represent a different entity; metabolic risk lower when hyperandrogenism absent
Role of AMH	Possible adjunct to replace PCOM ^[6]^A1a^[11]^D5	Not yet validated; assay variability limits use ^[11]^D5	2023 guideline recommends against AMH alone for diagnosis ^[2]^A1c	Research continues; population-specific cut-offs needed
Name change	PCOS retained	Rename to PMOS ^[14]^D5	Consensus process ongoing	Aim to reduce stigma and improve scientific accuracy

Understanding the underlying axis physiology, the hypothalamic-pituitary-ovarian (HPO) axis disruption driving hyperandrogenism and anovulation, is essential to interpreting these diagnostic criteria, as discussed in the next section.

Pearl: Phenotype D (normoandrogenic PCOS) is the most debated; the Androgen Excess Society considers hyperandrogenism essential for diagnosis ^[1]^A1c, and this phenotype carries lower metabolic risk, always assess for alternative causes of anovulation before labeling.

Axis Physiology, Pathophysiology and Biochemical Signature

▸PCOS pathophysiology involves a self-reinforcing triangle of neuroendocrine dysregulation (elevated LH pulse frequency), insulin resistance (post-receptor signaling defect with selective PI3K-AKT impairment), and ovarian hyperandrogenism (theca cell CYP17A1 hyperresponsiveness).
▸Insulin drives androgen generation in theca cells and peripheral adipose tissue via AKR1C3, while suppressing SHBG, creating a hyperandrogenic milieu even in lean women.
▸Adipose tissue dysfunction, including impaired GLUT4, dysregulated lipolysis, and low adiponectin, is a core mediator of metabolic complications, independent of obesity.
▸Genetic susceptibility involves common variants in AKT2, DENND1A, and gonadotropin receptor genes, with rare monogenic forms (INSR, LMNA, PPARG) mimicking severe PCOS.

HY High Yield: A low SHBG with an elevated free androgen index is the most consistent biochemical abnormality across PCOS phenotypes; a normal LH:FSH ratio does not exclude PCOS, especially in obese women.

Having established the diagnostic framework, the pathophysiologic architecture of PCOS can be understood as a self-reinforcing triangle of neuroendocrine dysregulation, insulin resistance, and ovarian hyperandrogenism. The normal negative-feedback loop is disrupted at multiple nodes, each amplifying the next.

Neuroendocrine Dysregulation

The hypothalamic-pituitary-ovarian axis in PCOS exhibits a characteristic increase in luteinizing hormone (LH) pulse frequency and amplitude, driven by diminished sensitivity of the hypothalamic GnRH pulse generator to progesterone-mediated negative feedback ^[23]^D5. This results in an elevated LH:FSH ratio, typically >2, which preferentially stimulates theca cells to produce androgens while limiting follicular maturation. The elevated LH is a consequence of chronic hyperandrogenism and hyperinsulinemia, which reduce hypothalamic progesterone receptor expression ^[23]^D5. Anti-Müllerian hormone (AMH), produced by granulosa cells of small antral follicles, is also elevated in PCOS (often >4.7 ng/mL) and contributes to GnRH pulse dysregulation by directly modulating hypothalamic kisspeptin neurons ^[51]^D5. The resulting LH excess drives theca cell steroidogenesis, perpetuating the cycle.

Ovarian Steroidogenesis and the Androgen Excess

Ovarian theca cells from women with PCOS are constitutively hyperresponsive to LH, with increased expression of CYP17A1 (17α-hydroxylase/17,20-lyase), the key enzyme in androgen biosynthesis ^[23]^D5. This intrinsic theca cell defect is further amplified by insulin, which acts as a co-gonadotropin through its cognate receptor on theca cells, upregulating CYP17A1 activity ^[50]^D5. Insulin also suppresses hepatic sex hormone-binding globulin (SHBG) production, raising free testosterone levels. In adipose tissue, insulin stimulates aldoketoreductase type 3 (AKR1C3), which converts androstenedione to testosterone, creating an additional peripheral source of androgen generation ^[45]^B3b. The net result is biochemical hyperandrogenism: elevated total and free testosterone, androstenedione, and dehydroepiandrosterone sulfate (DHEAS), with a low SHBG and a high free androgen index (FAI).

Insulin Resistance and Adipose Dysfunction

Insulin resistance is a hallmark of PCOS, present in 50-70% of affected women and independent of obesity ^[50]^D5. The defect is post-receptor: in skeletal muscle and adipocytes, insulin receptor signaling shows increased serine phosphorylation of IRS-1, which selectively impairs the metabolic (PI3K-AKT) pathway while preserving mitogenic (MAPK-ERK) signaling ^[50]^D5. This uncoupling explains why hyperinsulinemia coexists with preserved ovarian steroidogenic responsiveness. Adipose tissue dysfunction is a key mediator: even in lean PCOS, adipocytes exhibit impaired glucose transport (GLUT4 downregulation), dysregulated lipolysis, and altered adipokine secretion (low adiponectin, elevated cytokines) ^[29]^B2a. These abnormalities drive systemic insulin resistance and chronic low-grade inflammation, further worsening hyperandrogenism via direct ovarian effects and reduced SHBG.

Genetic and Environmental Modifiers

PCOS is a complex genetic trait. Genome-wide association studies have identified >20 susceptibility loci, including those near the LH receptor, FSH receptor, DENND1A, and THADA, though the effect sizes are modest ^[13]^D5^[23]^D5. Rare monogenic forms exist: mutations in the insulin receptor (INSR) cause type A insulin resistance syndrome, which phenocopies severe PCOS ^[63]^C4; mutations in LMNA (lamin A/C) or PPARG (peroxisome proliferator-activated receptor gamma) cause with secondary PCOS ^[36]^C4^[42]^C4. Common variants in AKT2 (a key node in insulin signaling) increase the odds of PCOS (OR 2.2 for rs3730051) ^[40]^B3b. Mendelian randomization studies suggest that obesity, elevated testosterone, and fasting insulin are causal risk factors for PCOS, while PCOS itself does not directly cause type 2 diabetes or coronary heart disease after accounting for obesity ^[39]^D5. Epigenetic mechanisms, including DNA methylation and microRNA dysregulation (e.g., miR-93, miR-21), are increasingly recognized as contributors to the heritable and variable expression of the syndrome ^[64]^D5. Environmental endocrine disruptors, particularly persistent organic pollutants such as perfluorooctane sulfonate (PFOS) and p,p'-DDE, have been associated with PCOS risk, with testosterone mediating 49% of the PFOS effect in one case-control study ^[61]^B3b.

Biochemical Signature

The laboratory profile that fingerprints PCOS is summarized in the table below. The combination of an elevated LH:FSH ratio, elevated free testosterone or FAI, low SHBG, and elevated AMH is highly suggestive, though not all components are present in every phenotype ^[9]^A1c^[23]^D5.

Biomarker	Typical Finding in PCOS	Mechanism
LH:FSH ratio	>2 (especially in lean women)	Increased GnRH pulse frequency; reduced progesterone feedback ^[23]^D5
Free testosterone / FAI	Elevated	Theca cell hyperresponsiveness to LH; insulin-driven AKR1C3 in adipose ^[45]^B3b
SHBG	Low	Suppressed by insulin and androgens ^[23]^D5
AMH	>4.7 ng/mL	Increased antral follicle pool; granulosa cell overproduction ^[51]^D5
Fasting insulin / HOMA-IR	Elevated	Post-receptor insulin signaling defect; adipose dysfunction ^[50]^D5
Adiponectin	Low	Adipocyte dysfunction; inversely correlated with insulin resistance ^[29]^B2a

Pearl: The biochemical signature of PCOS is a triad of elevated LH/FSH ratio, elevated free androgen index, and low SHBG, with or without elevated fasting insulin, reflecting the intertwined neuroendocrine and metabolic axes. A single normal value does not exclude the diagnosis.

Epidemiology, Etiology and Risk Factors

▸Global PCOS prevalence is 9.8% by Rotterdam criteria and 6.3% by 2023 Guideline criteria, varying by region from 2.9% to 11.4%.
▸Obesity is the strongest modifiable risk factor; a 1% increase in obesity prevalence is associated with a ~0.4% increase in PCOS prevalence.
▸Genetic susceptibility includes FTO variant rs9939609 (OR 1.30) and familial clustering; TCF7L2 variants are not associated.
▸PCOS carries increased risks of type 2 diabetes (HR 3.23), endometrial cancer (RR 3.46), all-cause mortality (HR 1.33), and psychiatric comorbidities (depression 37%, anxiety 48%).

HY High Yield: PCOS prevalence varies by diagnostic criteria: 9.8% using Rotterdam vs 6.3% using 2023 Guideline criteria. The stricter criteria reduce overdiagnosis in adolescents by excluding polycystic ovarian morphology, which overlaps with normal puberty [78].

From the disrupted hypothalamic-pituitary-ovarian axis and insulin-driven hyperandrogenism emerges a syndrome that affects a substantial fraction of the reproductive-age population. PCOS is the most common endocrine disorder in women of reproductive age, with a global prevalence of 9.8% (95% CI 7.2-12.3) when diagnosed by the 2003 Rotterdam criteria, and 6.3% (95% CI 3.9-8.8) using the stricter 2023 International Evidence-based Guideline criteria that exclude polycystic ovarian morphology in adolescents ^[78]^B2c. Prevalence varies by world region: under guideline criteria, it ranges from 2.9% (95% CI 2.0-3.9) in the Western Pacific to 11.4% (95% CI 7.1-15.7) in South-East Asia ^[78]^B2c. The disorder affects approximately 1 in 15 women worldwide ^[15]^D5, with up to 15% affected depending on diagnostic criteria ^[22]^D5.

Risk Factors and Genetic Susceptibility

Obesity is the strongest modifiable risk factor. A systematic review found that a 1% increase in obesity prevalence is associated with an approximately 0.4% increase in PCOS prevalence by Rotterdam criteria ^[72]^B2a. The association is bidirectional: obesity exacerbates PCOS features, and PCOS predisposes to weight gain. Genetic factors contribute substantially. The FTO variant rs9939609, which predisposes to common obesity, increases PCOS risk with an odds ratio of 1.30 (95% CI 1.12-1.51) per minor allele copy, an effect largely mediated through adiposity ^[89]^B3b. In contrast, common variants in TCF7L2, strongly linked to type 2 diabetes, show no association with PCOS, indicating distinct genetic architectures ^[90]^B3b. Familial clustering is well documented; brothers of women with PCOS exhibit a 38% reduction in insulin sensitivity and increased glucose intolerance, independent of obesity ^[88]^B3b. Premature adrenarche, characterized by pre-pubertal adrenal androgen excess, is considered a forerunner of PCOS and is associated with higher fasting insulin levels ^[77]^B2a. Thyroid autoimmunity, particularly Hashimoto's thyroiditis, is more prevalent in PCOS, though a shared genetic basis remains unconfirmed ^[84]^D5.

Risk Factor	Odds Ratio / Relative Risk	Evidence Level
Obesity (per 1% increase in prevalence)	~0.4% increase in PCOS prevalence ^[72]^B2a	2a (systematic review)
FTO rs9939609 (per minor allele)	OR 1.30 (95% CI 1.12-1.51) ^[89]^B3b	3b (case-control)
Family history (first-degree relative)	Not quantified; strong clustering ^[23]^D5	5 (expert opinion)
Premature adrenarche	Higher fasting insulin; OR not reported ^[77]^B2a	2a (meta-analysis)
Hashimoto's thyroiditis	Increased prevalence; OR not reported ^[84]^D5	5 (narrative review)

Temporal Trends and Special Considerations

PCOS prevalence appears to be rising in parallel with the global obesity epidemic, though causality cannot be established from observational data ^[72]^B2a. The condition carries substantial long-term health risks. Women with PCOS have an increased overall mortality (adjusted HR **1.33, 95% **), driven by neoplasms (HR 1.39) and circulatory diseases (HR 1.68) ^[80]^B3b. The incidence of type 2 diabetes is 4.19 per 1000 person-years in PCOS versus 1.02 in controls (HR 3.23), with the highest relative risk in lean women ^[81]^B2b. risk is elevated (pooled RR **3.46, 95% **), contributing an estimated excess annual US healthcare cost exceeding $467 million ^[74]^B2a. Psychiatric comorbidity is common: the prevalence of major depressive disorder in PCOS is 37.0% (95% CI 29.0-44.0) and anxiety **48.0% ** ^[91]^B2a; odds of any eating disorder are increased (OR 1.53, 95% CI 1.29-1.82) ^[73]^B2a. Obstructive sleep apnea is more frequent and, when present, increases the risk of pulmonary embolism (HR **1.95, 95% **) ^[104]^B2b. These epidemiological patterns set the stage for the diverse clinical manifestations discussed next.

Pearl: The strongest modifiable risk factor for PCOS is obesity; a 1% population-level increase in obesity prevalence is associated with a ~0.4% rise in PCOS prevalence, and weight loss of 5-7% significantly improves ovulation rates and metabolic outcomes ^[69]^A1b^[72]^B2a.

Clinical Presentation

▸PCOS presents with a triad of menstrual irregularity, hyperandrogenism, and polycystic ovarian morphology, but the clinical picture is heterogeneous and evolves with age.
▸Phenotype A (hyperandrogenism + ovulatory dysfunction + PCOM) carries the highest metabolic risk; phenotype D (normoandrogenic) is the mildest but diagnosis remains controversial.
▸Red flags include signs of virilization (suggesting tumor), severe insulin resistance (monogenic syndromes), and high rates of depression/anxiety requiring routine screening.

HY High Yield: A normal mFG score (< 4) does not exclude hyperandrogenism; up to 30% of women with biochemical hyperandrogenism have no hirsutism, especially in Asian populations [108].

! Warning: Total testosterone > 200 ng/dL or rapid-onset virilization warrants immediate imaging for an androgen-secreting tumor [13, 67].

From the epidemiologic contours of PCOS, a syndrome affecting 5-18% of reproductive-age women, with prevalence varying from 10.8% in Asian to 16.0% in Caucasian populations ^[108]^C4, the clinical picture emerges as a tapestry of hyperandrogenism, ovulatory disruption, and metabolic dysfunction that evolves across the lifespan ^[115]^B2b. The presentation is heterogeneous, but the unifying thread is androgen excess, whether biochemical or clinical, driving the visible and visceral features of the syndrome ^[13]^D5^[67]^A1c.

Presenting Symptoms

The patient typically presents in adolescence or early adulthood with one or more of three cardinal complaints: menstrual irregularity, hyperandrogenic symptoms, or infertility ^[13]^D5^[114]^D5. Oligomenorrhea (fewer than eight cycles per year) or secondary amenorrhea (≥90 days without menses) is the most common menstrual pattern, reflecting chronic anovulation ^[110]^D5. Hirsutism, coarse, dark hair in a male pattern on the upper lip, chin, chest, lower abdomen, back, and inner thighs, develops gradually after menarche and worsens with weight gain ^[114]^D5. Acne, particularly on the jawline, chest, and back, and androgenetic alopecia (vertex thinning with preserved frontal hairline) are also common ^[13]^D5. Infertility, driven by anovulation, is the presenting complaint in up to 40% of women seeking care ^[13]^D5.

Examination Findings

Physical examination should systematically assess for signs of hyperandrogenism, central obesity, and insulin resistance. Hirsutism is quantified by the modified Ferriman-Gallwey (mFG) score, with a score ≥ 4-6 considered abnormal depending on ethnicity ^[13]^D5^[67]^A1c. Acne, seborrhea, and , a velvety, hyperpigmented patch on the nape of the neck, axillae, groin, or knuckles, signal underlying insulin resistance ^[114]^D5. Body mass index (BMI) > 30 kg/m² is present in 40-60% of women with PCOS, but lean PCOS (BMI < 25 kg/m²) occurs in 20-30% of affected women, especially in Asian populations ^[13]^D5^[108]^C4. Waist circumference > 88 cm (or > 80 cm in Asian women) indicates central adiposity, which amplifies metabolic risk ^[109]^C4. Blood pressure is often elevated, with a mean systolic BP of 135/85 mm Hg in the classic presentation ^[114]^D5.

Phenotypic Variants

The Rotterdam criteria yield four phenotypes, which differ in severity and metabolic risk ^[13]^D5^[106]^D5:

Phenotype	Androgen Excess	Ovulatory Dysfunction	PCOM	Frequency	Metabolic Risk
A (classic)	Yes	Yes	Yes	45-65%	Highest
B (non-PCOM)	Yes	Yes	No	8-15%	High
C (ovulatory)	Yes	No	Yes	16-30%	Moderate
D (normoandrogenic)	No	Yes	Yes	10-20%	Lowest

Phenotype A carries the most severe metabolic profile, with higher BMI, insulin resistance, and metabolic syndrome prevalence ^[13]^D5^[115]^B2b. Phenotype D (normoandrogenic) is controversial; some argue it represents a milder variant or a separate entity, but the Rotterdam consensus includes it ^[106]^D5.

Red Flags

Certain features demand urgent evaluation: Signs of virilization (clitoromegaly, deepening voice, rapid-onset hirsutism, temporal balding) suggest a secondary androgen-secreting tumor (e.g., ovarian or adrenal) and require imaging and total testosterone > 200 ng/dL ^[13]^D5^[67]^A1c. Severe insulin resistance with acanthosis nigricans and BMI > 35 kg/m² may indicate a monogenic insulin resistance syndrome (e.g., Dunnigan-type due to LMNA mutation), which responds to thiazolidinediones but not to ^[36]^C4. Obstructive sleep apnea, suggested by morning headaches, daytime somnolence, witnessed apneas, is present in 30-50% of women with PCOS and exacerbates and glucose intolerance ^[123]^A1c. Depression and anxiety affect 51% and 45% of women with PCOS, respectively, in low- and middle-income countries, and should be screened for routinely ^[122]^B2a^[111]^C4.

Atypical Presentations

PCOS may present silently in lean women with normal menses but biochemical hyperandrogenism and polycystic ovaries (phenotype C) ^[106]^D5. Postmenopausal women with PCOS may have enduring hyperandrogenism, but diagnostic criteria are less established ^[67]^A1c. Adolescents pose a diagnostic challenge because physiologic anovulation and acne mimic PCOS; the Endocrine Society recommends requiring both hyperandrogenism and menstrual irregularity, and excluding ovarian morphology due to poor specificity ^[105]^D5. Premature adrenarche in childhood, precocious pubic hair, acne, accelerated growth, is a forerunner of PCOS and is associated with higher fasting insulin (mean difference 15.0 pmol/L) and BMI ^[77]^B2a. Age-related shifts occur: younger women (20-24 years) have higher LH, FSH, total testosterone, and AMH levels, while older women (35-40 years) develop more pronounced metabolic syndrome, dyslipidemia, and hypertension, with lower HDL and higher triglycerides ^[115]^B2b.

Pearl: In a woman presenting with hirsutism and oligomenorrhea, a total testosterone > 200 ng/dL or rapid-onset virilization should prompt imaging for an androgen-secreting tumor before attributing the findings to PCOS ^[13]^D5; conversely, a normal mFG score (< 4) does not exclude hyperandrogenism, up to 30% of women with biochemical hyperandrogenism have no hirsutism, particularly in Asian populations ^[108]^C4.

Diagnosis and Workup

▸Diagnosis requires two of three Rotterdam criteria: hyperandrogenism, irregular cycles, and polycystic ovarian morphology (or elevated AMH in adults).
▸In adolescents, both hyperandrogenism and irregular cycles are needed; ovarian morphology is not used.
▸Exclusion of non-classic CAH is mandatory via 17-OHP with ACTH stimulation testing when indicated.

Dx Diagnostic Essentials: The gold-standard diagnostic test for PCOS is the clinical application of the Rotterdam criteria (two of three: hyperandrogenism, irregular cycles, polycystic ovarian morphology) with exclusion of other disorders. In adolescents, both hyperandrogenism and irregular cycles are required.

HY High Yield: Do not rely on a single testosterone level alone; use free testosterone or free androgen index. Always measure 17-OHP to exclude non-classic CAH before labeling a patient with PCOS.

From a clinical presentation dominated by hyperandrogenism and menstrual irregularity, the diagnostic workup aims to confirm the diagnosis using validated criteria, establish the phenotype, and exclude disorders that mimic PCOS. The International Evidence-based Guideline recommends the Rotterdam criteria for adults: the presence of at least two of three features, hyperandrogenism (clinical or biochemical), irregular cycles, and polycystic ovarian morphology (PCOM) or elevated anti-Müllerian hormone (AMH) ^[2]^A1c^[9]^A1c. In adolescents, both hyperandrogenism and irregular cycles are required; PCOM is excluded because it overlaps with normal pubertal development, reducing specificity ^[78]^B2c^[129]^D5. Using these criteria, the global prevalence of PCOS in adolescents is 6.3% (95% CI 3.9-8.8), compared with 9.8% (95% CI 7.2-12.3) when the older Rotterdam criteria were applied ^[78]^B2c.

Biochemical Assessment

Biochemical hyperandrogenism is confirmed by elevated total testosterone, free testosterone (or calculated free androgen index), androstenedione, or dehydroepiandrosterone sulfate (DHEAS). Liquid chromatography-tandem mass spectrometry (LC-MS/MS) is the preferred method for accurate measurement, especially at low concentrations ^[3]^D5. Sex hormone-binding globulin (SHBG) should be measured; low levels increase the free androgen fraction and worsen clinical hyperandrogenism. The 2023 Guideline also recommends a 75-g oral glucose tolerance test (OGTT) at diagnosis to screen for impaired glucose tolerance, though this is not part of the diagnostic criteria ^[2]^A1c^[9]^A1c.

All women with suspected PCOS require exclusion of alternative causes of hyperandrogenism (see Table). The most critical differential is non-classic (NCAH) due to 21-hydroxylase deficiency. A fasting morning 17-hydroxyprogesterone (17-OHP) level should be measured; a value >6 nmol/L (≈2 ng/mL) warrants an ACTH stimulation test (250 μg cosyntropin with 17-OHP measured at 60 minutes). A stimulated 17-OHP >10 ng/mL (≈30 nmol/L) is diagnostic of NCAH ^[141]^D5. Additional tests include prolactin, thyroid-stimulating hormone, insulin-like growth factor 1 (IGF-1), and morning cortisol (to screen for Cushing syndrome). Androgen-secreting tumors are rare but should be considered when testosterone is >5 nmol/L (≈150 ng/dL) or DHEAS is markedly elevated, especially with rapid onset of virilization ^[128]^D5.

Imaging

Transvaginal ultrasound is the standard for determining PCOM. Using a high-frequency probe (≥8 MHz), the follicle number per ovary (FNPO) should be ≥20 and/or ovarian volume ≥10 mL in either ovary ^[2]^A1c^[9]^A1c. The threshold applies to adults; in adolescents, ultrasound is not recommended for diagnosis ^[78]^B2c. AMH is a surrogate marker that correlates strongly with antral follicle count and offers a non-invasive option, but it is not yet a formal diagnostic criterion due to inter-assay variability and lack of universally accepted cutoffs. Proposed cutoffs range from 3.5 to 5 ng/mL ^[11]^D5.

Differential Diagnosis

Condition	Key distinguishing features	Diagnostic test
Non-classic CAH (21-hydroxylase deficiency)	Family history, premature pubarche, elevated 17-OHP	ACTH stimulation test, 17-OHP >10 ng/mL at 60 min ^[141]^D5
Cushing syndrome	Proximal muscle weakness, striae, easy bruising, central obesity	24-h urine free cortisol, overnight suppression test, late-night salivary cortisol
Androgen-secreting tumor	Rapid onset of virilization, testosterone >5 nmol/L	Ovarian/adrenal imaging (CT, MRI, transvaginal ultrasound) ^[128]^D5
	Galactorrhea, amenorrhea	Serum prolactin
Thyroid dysfunction	Symptoms of hypo- or hyperthyroidism	TSH, free T4
	Coarse facial features, large hands/feet, joint pain	IGF-1, oral glucose tolerance test for GH suppression
Type A insulin resistance syndrome (TAIRS)	Severe hyperinsulinemia, , non-obese phenotype, often onset in adolescence	INSR gene sequencing ^[63]^C4

Diagnostic Algorithm

History and physical examination: Assess for hirsutism (modified Ferriman-Gallwey score ≥4-6), acne, alopecia, menstrual pattern (oligomenorrhea <8 cycles per year, amenorrhea), and acanthosis nigricans. Record BMI and waist circumference.
First-line laboratory panel: Total testosterone, free testosterone (or calculated free androgen index), SHBG, DHEAS, 17-OHP, prolactin, TSH, and fasting glucose. If 17-OHP is elevated, proceed to ACTH stimulation test.
OGTT: 75-g OGTT with glucose and insulin at 0, 60, and 120 minutes to assess glucose tolerance, even if fasting glucose is normal ^[2]^A1c.
Imaging: Transvaginal ultrasound for PCOM (FNPO ≥20, ovarian volume ≥10 mL). If ultrasound is not feasible or inconclusive, AMH may be used as a surrogate (cutoff 3.5-5 ng/mL) ^[11]^D5.
Phenotype classification: Based on the combination of criteria present, phenotype A (hyperandrogenism + irregular cycles + PCOM), B (hyperandrogenism + irregular cycles), C (hyperandrogenism + PCOM), D (irregular cycles + PCOM) ^[3]^D5.
Referral: If NCAH is confirmed, refer to endocrinology; if androgen-secreting tumor is suspected, refer for imaging and surgical evaluation.

Pearl: One-third of women with PCOS report a diagnostic delay of >2 years, and fewer than 16% are satisfied with the information they receive at diagnosis ^[130]^C4. Applying the 2023 International Guideline criteria, including the use of AMH as a surrogate for PCOM in adults, can streamline diagnosis and reduce unnecessary delays.

Differential Diagnosis of Hyperandrogenism in Women with Suspected PCOS

Condition	Key distinguishing features	Diagnostic test
Non-classic CAH (21-hydroxylase deficiency)	Family history, premature pubarche, elevated 17-OHP	ACTH stimulation test, 17-OHP >10 ng/mL at 60 min
Cushing syndrome	Proximal muscle weakness, striae, easy bruising, central obesity	24-h urine free cortisol, overnight dexamethasone suppression test, late-night salivary cortisol
Androgen-secreting tumor	Rapid onset of virilization, testosterone >5 nmol/L	Ovarian/adrenal imaging (CT, MRI, transvaginal ultrasound)
Hyperprolactinemia	Galactorrhea, amenorrhea	Serum prolactin
Thyroid dysfunction	Symptoms of hypo- or hyperthyroidism	TSH, free T4
Acromegaly	Coarse facial features, large hands/feet, joint pain	IGF-1, oral glucose tolerance test for GH suppression
Type A insulin resistance syndrome (TAIRS)	Severe hyperinsulinemia, acanthosis nigricans, non-obese phenotype, often onset in adolescence	INSR gene sequencing

Severity, Staging and Risk Stratification

▸PCOS phenotypes (A-D) stratify metabolic and reproductive risk, guiding treatment intensity and surveillance intervals.
▸All women with PCOS require cardiometabolic screening (OGTT, lipids) and mental health screening at diagnosis and annually.
▸Bone health assessment is stratified by BMI, with BMI <27 kg/m² conferring increased fracture risk despite lower body weight.

HY High Yield: Phenotype A and B (hyperandrogenism + ovulatory dysfunction) carry the highest metabolic risk; phenotype D (normoandrogenic anovulation) has the lowest metabolic burden but still requires endometrial surveillance.

Once the diagnosis of PCOS is confirmed using the , the next step is to stratify the patient by phenotype and assess concurrent metabolic, reproductive, and psychological risks that dictate treatment intensity and surveillance intervals.

Phenotype Classification and Severity

The Rotterdam criteria yield four phenotypes: A (hyperandrogenism + ovulatory dysfunction + PCOM), B (hyperandrogenism + ovulatory dysfunction), C (hyperandrogenism + PCOM), and D (ovulatory dysfunction + PCOM). Phenotypes A and B, which include both hyperandrogenism and ovulatory dysfunction, carry the highest metabolic risk, including insulin resistance, type 2 diabetes, and metabolic syndrome ^[2]^A1c^[9]^A1c. Phenotype C (ovulatory with hyperandrogenism) has intermediate risk, while phenotype D (normoandrogenic anovulation) has the lowest metabolic burden but still requires surveillance for due to unopposed estrogen ^[67]^A1c. The 2023 International Guideline recommends using this phenotype-based stratification to guide intensity ^[2]^A1c.

Metabolic Risk Stratification

All women with PCOS should undergo screening for impaired glucose tolerance (75-g ) and lipid profile at diagnosis, with annual reassessment if abnormal ^[2]^A1c^[9]^A1c. The prevalence of metabolic syndrome is high, and a three-component lifestyle intervention (cognitive behavioral therapy, diet, exercise) reduced metabolic syndrome prevalence by 21.6% (P=0.037) in one RCT ^[71]^A1b. For obese women with PCOS who have poor response to , adding 1.2 mg daily led to mean weight loss of 6.5 kg over 12 weeks ^[28]^A1b. A meta-analysis of GLP-1 receptor agonists showed significant reduction in BMI (MD -1.09 kg/m²) and HOMA-IR (SMD -0.38) ^[153]^A1a. Bone health is also stratified by BMI: women with PCOS and BMI <27 kg/m² have lower vertebral and nonvertebral bone density and increased bone resorption markers, while those with BMI ≥27 have increased bone density ^[5]^A1a. This has implications for fracture risk assessment.

Reproductive and Oncologic Risk

Anovulatory phenotypes (A, B, D) carry risk of endometrial hyperplasia and cancer due to unopposed estrogen. The Endocrine Society guideline recommends endometrial surveillance (ultrasound or biopsy) in women with prolonged amenorrhea (>3-4 months) or abnormal bleeding ^[67]^A1c. For fertility, is superior to for ovulation induction, especially in hyperandrogenic phenotypes (A, B, C) ^[151]^B2b. Phenotype D patients show comparable efficacy between the two agents ^[151]^B2b.

Psychological and Quality-of-Life Risk

Psychiatric comorbidities are highly prevalent: depression in 37% and anxiety in 48% of women with PCOS ^[91]^B2a. Adolescents and young adults (AYA) with PCOS have 2.48 times higher odds of psychiatric diagnosis and 2.14 times higher odds of psychotropic medication prescription compared to controls ^[154]^B3b. Eating disorders ( , ) are increased (OR 1.53) ^[73]^B2a. Body image concerns are significantly worse, with higher dissatisfaction on MBSRQ-AS subscales ^[7]^A1a. The 2023 guideline recommends routine screening for depression, anxiety, and disordered eating, especially before initiating lifestyle interventions ^[2]^A1c^[9]^A1c.

Risk Stratification Summary

Risk Domain	High-Risk Features	Recommended Action
Metabolic	Phenotype A/B, BMI ≥30, IGT, family history T2D	OGTT, lipid panel annually; lifestyle intervention; consider metformin/GLP-1 RA
Reproductive	Anovulation, prolonged amenorrhea	Endometrial surveillance; letrozole for ovulation induction
Psychological	Depression, anxiety, eating disorder symptoms	Screen with validated tools; refer to mental health
Bone	BMI <27 kg/m²	Consider ; ensure calcium/vitamin D
OSA	Obesity, snoring, daytime sleepiness	Screen with ; refer for ^[123]^A1c

Pearl: Phenotype A and B PCOS carry the highest metabolic and cardiovascular risk and warrant aggressive lifestyle and pharmacologic intervention, while phenotype D requires primarily endometrial surveillance and fertility management; all phenotypes benefit from routine mental health screening.

Acute Management and Endocrine Emergencies

▸Acute hypertriglyceridemia‑induced pancreatitis is a rare but life‑threatening complication in PCOS patients with lipodystrophy; immediate triglyceride‑lowering therapy is required.
▸Valproate exposure is strongly associated with incident PCOS (HR up to 7.08 for >365 DDDs) and should be avoided in women of reproductive age when possible.
▸Acute ketone monoester supplementation improves endothelial function and glycemic control during hyperglycemia in PCOS, though it is not yet a standard of care.

! Warning: Valproate use in women of reproductive age is associated with a dose‑dependent increase in PCOS risk (HR 4.43-7.08) [167]. Avoid valproate when possible; if used, monitor for menstrual irregularities and hyperandrogenism.

Severity stratification identifies patients at highest risk for acute metabolic complications. Although PCOS itself does not typically precipitate classic endocrine crises such as DKA or , several acute scenarios demand time‑critical intervention, particularly in women with concurrent , severe , or rapid androgen excess.

Step 1: Acute Hypertriglyceridemia and Pancreatitis

Patients with PCOS and underlying lipodystrophy syndromes (e.g., PPARG‑related lipodystrophy, congenital generalized lipodystrophy type 1) are at high risk for extreme hypertriglyceridemia and recurrent acute pancreatitis. In a cohort of 26 patients with PPARG variants, 78% had hypertriglyceridemia and 58% had acute pancreatitis ^[42]^C4. Similarly, a patient with CGL1 and nonclassic (NCAH) experienced 7 episodes of acute pancreatitis over 5 years due to extreme hypertriglyceridemia ^[157]^C4.

: Acute pancreatitis from hypertriglyceridemia is managed per standard guidelines: aggressive intravenous fluids, pain control, and early enteral nutrition. Triglyceride‑lowering therapy should be initiated emergently, with options including insulin infusion (for very high triglycerides >1000 mg/dL), fibrates, omega‑3 fatty acids, and in severe cases, plasmapheresis. In the CGL1 patient, metreleptin therapy led to remission of hypertriglyceridemia ^[157]^C4, though this is a chronic, not acute, intervention. For patients with known lipodystrophy, prompt recognition of abdominal pain and measurement of serum triglycerides is essential.

Step 2: Acute Hyperandrogenism and Virilization

Rapid onset of severe hyperandrogenism (e.g., testosterone levels >200 ng/dL) warrants investigation for androgen‑secreting tumors or NCAH. In PCOS, gradual hyperandrogenism is typical, but acute exacerbations may occur. In the CGL1 patient with NCAH, replacement therapy from age 3.5 to 10 years resulted in cessation of menstruation and reduction of breast size ^[157]^C4 - this is a chronic management, not acute. For acute virilization, imaging and adrenal suppression testing are indicated. No specific acute pharmacotherapy is supported by the provided evidence, but antiandrogen agents (e.g., ) may be considered for symptom control on a non‑urgent basis.

Step 3: Acute Metabolic Decompensation

Postprandial hyperglycemia transiently impairs endothelial function in PCOS, with prolonged impairment at 120 minutes compared to controls (PCOS: 6.3 ± 0.4% vs. 4.0 ± 0.5% FMD, P < 0.01) ^[164]^C4. Acute ketone monoester (KME) supplementation (482 mg/kg, administered 30 min before an oral glucose tolerance test) reduced plasma glucose area under the curve and improved flow‑mediated dilation across the OGTT in both PCOS women and controls ^[164]^C4 (randomized, double‑blind, placebo‑controlled crossover, N = 10 PCOS). While not a standard emergency therapy, KME represents a potential non‑pharmacologic strategy for acute glycemic and vascular protection in PCOS.

Step 4: Drug‑Induced Acute PCOS

exposure is associated with an increased risk of PCOS, with hazard ratios rising from 4.43 for current cumulative exposure of 0-90 defined daily doses (DDDs) to 7.08 for >365 DDDs ^[167]^B2b. In women of reproductive age, acute exposure to valproate should be avoided; if necessary, monitor for development of PCOS symptoms and consider alternative mood stabilizers or antiseizure medications.

These acute scenarios are distinct from the chronic, treat‑to‑target strategies that follow initial stabilization. The next section discusses long‑term management paradigms for PCOS, including replacement, suppression, and definitive therapies.

Pearl: The most critical acute endocrine emergency in PCOS is hypertriglyceridemia‑induced pancreatitis, especially in patients with underlying lipodystrophy; prompt triglyceride lowering and standard pancreatitis management are life‑saving.

Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)

▸Lifestyle modification with 5-10% weight loss is the foundational intervention for all overweight/obese women with PCOS.
▸COCP is first-line for menstrual regulation and hyperandrogenism; metformin is first-line for metabolic dysfunction.
▸Bariatric surgery achieves PCOS remission in approximately 78% of women with severe obesity and should be considered early.

Rx Drug of Choice: For menstrual irregularity and hyperandrogenism: low-dose COCP (EE 20-35 mcg). For metabolic dysfunction: metformin 1500-2000 mg/day titrated to GI tolerance.

Once acute endocrine and metabolic risks are stabilized, long-term of PCOS shifts to a treat-to-target framework: regularizing menstrual cycles, suppressing hyperandrogenism, and optimizing metabolic health. The 2023 International Evidence-based Guideline emphasizes a shared decision-making model that targets the woman’s predominant complaint, reproductive, metabolic, or cosmetic, and titrates therapy to predefined biochemical and clinical endpoints ^[2]^A1c^[9]^A1c.

Step 1: Lifestyle Intervention as Foundation

All women with PCOS, particularly those with overweight or obesity, should receive structured lifestyle counseling incorporating dietary modification, physical activity, and behavioral strategies. A Cochrane review of 15 RCTs (498 participants) found that lifestyle intervention improved the free androgen index (MD -1.11, 95% CI -1.96 to -0.26) ^[118]^A1a. The 2023 guideline recommends at least 5% to 10% weight loss as a primary target, which reduces insulin resistance, lowers androgens, and restores ovulation in 30-50% of women ^[2]^A1c^[9]^A1c. Time-restricted eating (e.g., early TRE, 8:00 AM-6:00 PM) significantly reduced fasting insulin, HOMA-IR, and body weight in a 6-week RCT of 75 women with PCOS ^[189]^A1b. Yoga, as a complementary intervention, may improve anthropometric and psychological outcomes, though evidence is limited by small sample sizes and heterogeneity ^[192]^B2a.

Step 2: Pharmacotherapy for Menstrual Regularity and Hyperandrogenism

Combined (COCP) are first-line for women seeking cycle regulation and suppression of clinical hyperandrogenism (hirsutism, acne) ^[2]^A1c^[9]^A1c. A systematic review of 36 RCTs showed COCP superior to for reducing free androgen index (FAI) (MD 7.08, 95% CI 4.81-9.36) and testosterone (MD 0.48 nmol/L, 95% CI 0.32-0.64) ^[178]^A1a. Low-dose formulations (20-35 mcg ethinyl estradiol) are preferred to minimize venous thromboembolism risk; fourth-generation progestins (e.g., drospirenone) may offer additional antiandrogenic benefit but with higher VTE risk ^[184]^A1a. For women with contraindications or intolerance to COCP, metformin 1500-2000 mg/day (e.g., 850 mg BID ^[172]^C4 or 1 g BID ^[126]^C4) improves menstrual cyclicity and reduces insulin resistance, though it is less effective for hirsutism ^[2]^A1c^[97]^A1a. Combination of COCP and metformin may provide additive benefits for both hyperandrogenism and metabolic parameters ^[178]^A1a.

Step 3: Metabolic Targets and Insulin Sensitization

Metformin remains the primary insulin sensitizer for women with PCOS and metabolic syndrome, , or type 2 diabetes. A Cochrane meta-analysis of 48 RCTs (4451 women) found metformin improved live birth rates compared with placebo (OR 1.59, 95% CI 1.00-2.51) and reduced fasting insulin by -4.20 mIU/L (95% CI -7.68 to -0.73) ^[196]^A1a. Metformin also lowers serum ferritin (reflecting reduced body iron stores) and improves endothelial function, effects that are augmented by folate supplementation (400 mcg/day) ^[172]^C4^[186]^B2b. Thiazolidinediones (pioglitazone 30 mg/day) reduce sCD36 and hsCRP but carry an unfavorable risk-benefit profile in PCOS and are not recommended as first-line therapy ^[67]^A1c^[174]^A1b.

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are emerging as adjunctive therapies for weight loss and metabolic improvement in women with PCOS and obesity. A systematic review of 11 RCTs reported that GLP-1 RAs reduced BMI by a mean of -1.38 kg/m² (95% CI -2.39 to -0.38) compared with control ^[33]^A1a. In a 16-week RCT, 1.0 mg once weekly improved taste recognition and reduced putamen activation in response to food cues ^[125]^A1b. 1.2 mg daily added to metformin in a pilot study of 28 obese infertile women with PCOS increased live birth rate per embryo transfer (85.7% vs 28.6%, p=0.03) ^[175]^A1b. However, GLP-1 RAs are associated with a loss of lean body mass that accounts for approximately 28% of total weight loss ^[43]^A1a. A real-world cohort from Poland (n=38,263) showed that incretin-based therapy use in PCOS rose from 0.14% in 2018 to 5.97% in 2024, driven by weight-focused indications ^[60]^B2b.

Step 4: Definitive Treatment, Bariatric Surgery

For women with PCOS and severe obesity (BMI ≥35 kg/m²), bariatric surgery is the most effective treatment for achieving sustained remission of PCOS. The BAMBINI RCT randomized 80 women with PCOS and BMI ≥35 kg/m² to vertical sleeve or medical care; the surgical group had a median of 6 spontaneous ovulations over 52 weeks vs 2 in the medical group (incidence rate ratio 2.5, 95%) ^[79]^A1b. A prospective nonrandomized trial of 81 women with obesity and PCOS (BMI ≥27.5 kg/m²) reported complete remission of PCOS in 78% of the surgical group vs 15% in the medical group after 12 months ^[4]^B2b. The key predictor of remission was achieving a final BMI below 27.5 kg/m² (drug group) or 26 kg/m² (surgical group) ^[4]^B2b. Bariatric surgery does not consistently alter serum anti-Müllerian hormone levels, suggesting no significant long-term impact on ovarian reserve ^[191]^B2a.

Monitoring and Titration

Treatment should be reviewed every 3-6 months initially, then annually. Targets include: regular menstrual cycles (every 21-35 days), normalization of free androgen index (FAI <5), fasting glucose <100 mg/dL, HbA1c <5.7%, blood pressure <130/80 mmHg, and LDL-C <130 mg/dL ^[2]^A1c^[9]^A1c. For women on metformin, monitor renal function and vitamin B12 annually; consider folate supplementation if homocysteine is elevated ^[186]^B2b. For COCP users, reassess cardiovascular risk and VTE risk factors at each visit. For GLP-1 RA users, monitor for side effects and consider dual-energy X-ray absorptiometry if lean mass loss is a concern ^[43]^A1a.

Controversies and Guideline Disagreement

Question	Position A	Position B	Strength	Implication for practice
Should COCP or metformin be first-line for long-term management?	2023 International Guideline recommends COCP as first-line for menstrual/hyperandrogenism symptoms and metformin for metabolic dysfunction ^[2]^A1c^[9]^A1c	Endocrine Society 2013 suggests COCP first-line for hirsutism/acne, metformin for metabolic/glycemic abnormalities ^[67]^A1c	Mild (both prioritize symptom-based choice)	Clinicians should select therapy based on the woman’s predominant complaint and risk profile; combination may be beneficial.
Role of GLP-1 RAs in PCOS	2023 Guideline notes insufficient evidence for routine use, but allows as adjunct for weight loss in obesity ^[2]^A1c	European Society of Endocrinology acknowledges GLP-1 RAs may improve metabolic and reproductive outcomes in obese PCOS ^[3]^D5	Moderate (evidence level disagreement)	Use GLP-1 RAs off-label for weight management in PCOS with obesity after lifestyle failure; monitor for lean mass loss.
Bariatric surgery timing	2023 Guideline recommends considering bariatric surgery for women with PCOS and BMI ≥35 kg/m² after lifestyle failure ^[2]^A1c	Endocrine Society 2013 does not specifically address bariatric surgery in PCOS ^[67]^A1c	Moderate (lack of earlier recommendation)	Emerging evidence supports early surgical referral for severe obesity and PCOS, given high remission rates.

Drug / Modality Comparison Table

Option	Indication / Line	Dose or Specifics	Key Trial	Outcome	Evidence level
COCP (low-dose)	First-line for menstrual irregularity, hirsutism, acne	EE 20-35 mcg + progestin (e.g., norethindrone, CPA, drospirenone)	^[184]^A1a meta-analysis of 19 RCTs	Superior to metformin for FAI, testosterone, SHBG ^[178]^A1a	1a
Metformin	First-line for metabolic dysfunction, second-line for menstrual	500 mg BID, titrate to 850-1000 mg BID (1500-2000 mg/day)	^[196]^A1a Cochrane (48 RCTs)	Improves live birth (OR 1.59), reduces insulin, improves ovulation ^[196]^A1a	1a
GLP-1 RA (semaglutide)	Adjunct for weight loss in obesity	1.0 mg once weekly ^[125]^A1b	^[33]^A1a meta-analysis (11 RCTs)	Reduces BMI by -1.38 kg/m² ^[33]^A1a	1a
GLP-1 RA (liraglutide)	Adjunct for weight loss and fertility	1.2 mg daily ^[175]^A1b	^[175]^A1b pilot RCT (n=28)	Higher live birth per ET (85.7% vs 28.6%) ^[175]^A1b	1b
Bariatric surgery	Definitive therapy for severe obesity (BMI ≥35)	Sleeve gastrectomy	^[79]^A1b BAMBINI RCT (n=80)	2.5-fold increase in ovulation rate ^[79]^A1b	1b

Pearl: Long-term PCOS management should be individualized to the patient’s primary complaint: use COCP for hyperandrogenism/cycle control, metformin for metabolic syndrome, and consider bariatric surgery early for women with BMI ≥35 kg/m², as it offers the highest rates of disease remission (78% vs 15% with medical therapy) ^[4]^B2b^[79]^A1b.

History and Evolution of Treatment

▸The evolution of PCOS treatment reflects a shift from symptom-focused ovulation induction to a comprehensive metabolic and reproductive approach, driven by landmark trials.
▸Letrozole replaced clomiphene as first-line ovulation induction after the 2014 RCT showed superior live-birth rates (27.5% vs 19.1%) [76].
▸Bariatric surgery and GLP-1 agonists represent the most effective weight loss strategies, with emerging evidence for NK3 antagonists and ketone-based therapies targeting hyperandrogenism directly.

HY High Yield: The 2014 letrozole vs clomiphene trial [76] is the single most practice-changing study in PCOS infertility: letrozole now first-line, clomiphene second-line.

The preceding framework rests on a foundation of evidence that has evolved substantially over the past half-century, shifting from purely surgical approaches to a nuanced, phenotype-driven pharmacologic and lifestyle armamentarium.

Surgical Origins and the Shift to Medical Therapy

Ovarian , introduced in the 1930s, was the first established treatment for anovulatory PCOS. It restored ovulation in many women but was largely abandoned because of the high risk of post-surgical adhesions and the advent of medical ovulation induction ^[215]^A1a. Laparoscopic ovarian drilling (LOD) emerged in the 1980s as a less invasive alternative. Cochrane meta-analyses of up to nine trials (1210 women) found no difference in live birth rates between LOD and gonadotropin therapy (34% vs 38%), but LOD dramatically reduced multiple pregnancy rates (1% vs 16%; OR 0.13, 95% CI 0.03-0.52) ^[219]^A1a. LOD remains a second-line option for clomiphene-resistant patients, particularly when gonadotropin risks are unacceptable.

The Insulin Sensitizer Era

The recognition of insulin resistance as a core pathogenic driver in the 1990s opened a new therapeutic axis. In 1996, Nestler et al. demonstrated that 500 mg three times daily reduced serum insulin and ovarian cytochrome P450c17α activity, lowering free testosterone in obese women with PCOS ^[210]^C4. A landmark 1999 trial showed that D-chiro-inositol 1200 mg daily improved ovulatory function and decreased androgens, blood pressure, and triglycerides ^[209]^A1b. However, the 2007 Pregnancy in Polycystic Ovary Syndrome (PPCOS) trial (626 women) definitively answered the infertility question: clomiphene alone produced a live-birth rate of 22.5% versus 7.2% with metformin alone (P<0.001), establishing clomiphene as first-line for ovulation induction ^[181]^A1b. Metformin retained a role for metabolic/glycemic abnormalities and menstrual irregularities, but the 2013 Endocrine Society guideline concluded it had limited or no benefit for hirsutism, acne, or infertility ^[67]^A1c. Thiazolidinediones (pioglitazone) improved insulin sensitivity and reduced soluble CD36 ^[174]^A1b, but an unfavorable risk-benefit ratio, weight gain, fluid retention, potential cardiovascular concerns, precluded routine use ^[67]^A1c.

Ovulation Induction: From Clomiphene to Letrozole

Clomiphene citrate was the standard first-line ovulation induction agent for decades, but its anti-estrogenic effects on the endometrium and cervical mucus, plus a multiple pregnancy rate of 6-8%, limited its appeal. The 2014 double-blind multicenter trial by Legro et al. (750 women) changed practice: letrozole 2.5-7.5 mg daily for 5 days produced higher cumulative live births than clomiphene (27.5% vs 19.1%; rate ratio 1.44, 95% CI 1.10-1.87; P=0.007) and a higher ovulation rate (61.7% vs 48.3%; P<0.001), with no significant difference in congenital anomalies ^[76]^A1b. The 2023 international guideline now recommends letrozole as first-line pharmacologic treatment for ovulation induction ^[2]^A1c.

Lifestyle and Metabolic Interventions

Lifestyle modification, caloric restriction, exercise, and behavioral support, has been a cornerstone of management, yet high-quality trial evidence was scarce until recently. The 2015 Lifestyle-OCP trial (149 overweight women with PCOS) showed that a 16-week lifestyle intervention achieving ~6% weight loss eliminated the adverse metabolic effects of and improved ovulation rates (60% vs 46% with OCP alone) ^[69]^A1b. The 2021 Lifestyle in PCOS (LIPCOS) trial (183 women, BMI >25) demonstrated that a three-component intervention (cognitive behavioral therapy, diet, exercise) reduced metabolic syndrome prevalence by 25.9% compared with usual care (P=0.046) ^[71]^A1b. Time-restricted eating (TRE) has emerged as an effective strategy: a 6-month RCT found that a 6-hour TRE window (1 PM to 7 PM) produced weight loss of -4.32% (95% CI -6.20 to -2.44), comparable to daily calorie restriction ^[225]^A1b. Bariatric surgery represents the most potent weight loss intervention. The BAMBINI trial (80 women, BMI ≥35) randomized to vertical sleeve versus medical care; the surgical group had 2.5 times more spontaneous ovulations over 52 weeks (median 6 vs 2; incidence rate ratio 2.5, 95%;) ^[79]^A1b. Each 1% body weight reduction increased the odds of ovulatory recovery by 5.6% ^[226]^B2b.

Emerging Pharmacotherapies

Glucagon-like peptide-1 (GLP-1) receptor agonists have transformed weight management in PCOS. 1.2 mg daily added to metformin in obese women with prior poor response to metformin produced a mean weight loss of 6.5 kg over 12 weeks, versus 1.2 kg with metformin alone (P<0.001) ^[28]^A1b. In a pilot IVF study, liraglutide plus metformin increased pregnancy rates per embryo transfer to 85.7% versus 28.6% with metformin alone (P=0.03) ^[175]^A1b. 1.0 mg weekly improved taste recognition and altered brain responses to food cues in a 16-week placebo-controlled trial ^[125]^A1b. 5 mg weekly combined with metformin led to a mean weight loss of -10.4 kg over 16 weeks, with greater reductions in visceral adipose tissue and higher pregnancy rates than metformin alone ^[223]^A1b. The neurokinin 3 (NK3) receptor antagonist fezolinetant (60 or 180 mg/day) reduced total testosterone by -0.80 nmol/L (P<0.001) and LH by -10.17 IU/L (P<0.001) over 12 weeks in a phase 2a proof-of-concept study, offering a novel approach targeting the neuroendocrine drive of hyperandrogenism ^[203]^A1b. Ketone supplementation (β-hydroxybutyrate) acutely lowered free testosterone by 21% and fasting glucose by 10% in a crossover trial, suggesting a potential role for ketone-based therapies ^[176]^A1b. An AKR1C3 inhibitor (BAY1128688) increased serum androsterone without affecting ovarian function, identifying a response biomarker for future development ^[206]^C4.

Controversies and Guideline Disagreement

Question	Position A	Position B	Strength	Implication
First-line ovulation induction	Letrozole (2023 international guideline) ^[2]^A1c	Clomiphene (2013 Endocrine Society guideline) ^[67]^A1c	Strong for letrozole based on 2014 RCT ^[76]^A1b	Practice has shifted; clomiphene now second-line
Role of metformin for infertility	Not recommended as first-line (PPCOS trial) ^[181]^A1b	May be used in non-obese women or with clomiphene (Cochrane 2009) ^[99]^A1a	Moderate	Metformin reserved for metabolic indications
Frozen vs fresh embryo transfer in PCOS	Frozen preferred (higher live birth, lower OHSS) ^[179]^A1b	Fresh acceptable if OHSS risk low (non-PCOS data) ^[180]^A1b^[182]^A1b	Strong for PCOS	Elective freeze-all strategy standard in PCOS

Pearl: The treatment of PCOS has evolved from a single-minded focus on ovulation induction to a comprehensive, phenotype-driven strategy integrating lifestyle, metabolic therapy, and targeted pharmacotherapy, letrozole has replaced clomiphene as first-line for ovulation, GLP-1 agonists are transforming weight management, and NK3 antagonists represent a promising future axis targeting the neuroendocrine origin of hyperandrogenism.

Landmark Trials Shaping PCOS Treatment

Trial (Year)	Intervention	Key Finding	NNT/NNH
PPCOS (2007) ^[181]^A1b	Clomiphene vs metformin vs both	Clomiphene live birth 22.5% vs metformin 7.2% (P<0.001)	NNT = 7 for clomiphene vs metformin
Legro et al. (2014) ^[76]^A1b	Letrozole vs clomiphene	Letrozole live birth 27.5% vs 19.1% (P=0.007)	NNT = 12 for letrozole
Chen et al. (2016) ^[179]^A1b	Fresh vs frozen embryo transfer	Frozen live birth 49.3% vs 42.0% (P=0.004)	NNT = 14 for frozen
Fezolinetant (2021) ^[203]^A1b	NK3 antagonist vs placebo	Testosterone reduction -0.80 nmol/L (P<0.001)	NNH not reported

Multiglandular Syndromes, Genetic Context and Co-Axis Effects

▸PCOS/PMOS has a complex polygenic architecture with shared loci for type 2 diabetes and insulin resistance, including FTO, AKT2, and GSK3B polymorphisms.
▸Insulin resistance amplifies hyperandrogenism via theca cell co-gonadotropin action and adipose AKR1C3-mediated testosterone generation, creating a self-reinforcing cycle.
▸Syndromic associations (type 1 diabetes, premature adrenarche, MASLD) mandate cross-axis surveillance for metabolic disease and endometrial cancer risk.

HY High Yield: The FTO genotype effect on BMI in PCOS is >2 times greater than in the general population; this gene-metabolic context interaction may identify women who benefit most from lifestyle intervention.

The preceding evolution of treatment for PCOS, now re-named polyendocrine metabolic ovarian syndrome (PMOS) to reflect its multisystem pathophysiology ^[14]^D5, has clarified that the disorder is not confined to the ovary. The genetic architecture, co-axis endocrine perturbations, and syndromic associations demand a cross-axis surveillance approach that extends well beyond reproductive .

Genetic Architecture and Shared Loci

PCOS follows a complex polygenic inheritance pattern, with heritability estimates of 30-70% ^[22]^D5. Genome-wide association studies have identified susceptibility loci implicating pathways in gonadotropin secretion, ovarian steroidogenesis, and insulin signaling. The FTO rs9939609 single nucleotide polymorphism exerts a stronger effect on BMI and body weight in women with PCOS than in the general female population: each copy of the risk allele increases BMI by approximately 0.19 z-score units (95% CI 0.13-0.24), translating to a 3.3 kg/m² difference between TT and AA/CC homozygotes ^[235]^B3a. Polymorphisms in AKT2 and GSK3B, components of the insulin signaling cascade, independently confer increased odds of PCOS (OR 2.2 and 2.4, respectively), and carriers of risk haplotypes in both genes have a further elevated odds ratio of 3.1 ^[40]^B3b. A genome-wide cross-trait analysis demonstrated a positive genetic correlation between type 2 diabetes and PCOS that is partially independent of BMI (rg = 0.12, p = 0.03), and identified 16 pleiotropic loci affecting both traits, with a putative causal effect of fasting insulin on PCOS ^[237]^B2c. These findings indicate that insulin resistance is not merely a comorbid feature but is genetically intertwined with the syndrome.

Co-Axis Endocrine Perturbations

Insulin resistance, present in up to 70% of women with PCOS, acts as a co-gonadotropin through its cognate receptor on theca cells, amplifying ovarian androgen production ^[50]^D5. Insulin also drives adipose androgen generation by upregulating AKR1C3 expression in subcutaneous adipocytes, converting androstenedione to testosterone, a mechanism demonstrated both in vivo and in vitro ^[45]^B3b. Adipose tissue dysfunction in PCOS, independent of excess adiposity, includes impaired adipogenesis, dysregulated lipolysis, and adipokine dysregulation (e.g., reduced adiponectin), contributing to systemic inflammation and metabolic deterioration ^[29]^B2a. The resulting hyperandrogenemia further worsens insulin resistance, creating a vicious cycle.

Syndromic Associations and Overlap

Women with type 1 diabetes have a substantially higher prevalence of PCOS (24%, 95% CI 15-34) and hyperandrogenemia (25%) compared with the general population, likely mediated by supraphysiologic insulin doses acting on the ovary ^[31]^A1a. Premature adrenarche, characterized by pre-pubertal adrenal androgen excess, is associated with higher fasting insulin levels (mean difference 15.04 pmol/L, 95%) and may represent a forerunner of PCOS ^[77]^B2a. Obesity-related secondary hypogonadism in women (FOSH) is a distinct entity characterized by reduced LH pulsatility, contrasting with the increased GnRH drive typical of PCOS; however, obesity blunts LH pulse amplitude in both PCOS and non-PCOS women, complicating the phenotype ^[93]^D5. Metabolic dysfunction-associated steatotic liver disease (MASLD) shares pathophysiological mechanisms with PCOS, including adipose tissue dysfunction, hepatic lipogenesis driven by androgens, and insulin resistance, warranting routine transaminase screening ^[46]^D5.

Cross-Axis Surveillance Imperative

Given the genetic overlap with type 2 diabetes and the independent risk conferred by hyperinsulinemia, all women with PCOS should undergo annual screening for type 2 diabetes with an oral glucose tolerance test, regardless of BMI ^[237]^B2c. The elevated risk of and cancer (due to unopposed estrogen in anovulation) mandates vigilance for abnormal uterine bleeding, though routine screening in asymptomatic women is not currently recommended ^[239]^D5. The presence of PCOS should prompt evaluation for metabolic syndrome, MASLD, and cardiovascular risk factors, as these co-axis effects drive long-term morbidity ^[46]^D5.

Pearl: In any woman with PCOS/PMOS, the presence of insulin resistance, hyperandrogenism, and anovulation should trigger a systematic search for co-axis metabolic disease (type 2 diabetes, MASLD, dyslipidemia) and syndromic associations (type 1 diabetes, premature adrenarche), because the genetic architecture dictates that these are not coincidental but biologically linked, and early intervention can mitigate long-term sequelae.

Key Genetic Loci and Co-Axis Effects in PCOS/PMOS

Locus / Co-Axis	Effect Size or Association	Reference
FTO rs9939609	Each risk allele increases BMI by 0.19 z-score units (≈3.3 kg/m² between homozygotes)	^[235]^B3a
AKT2/GSK3B	OR 2.2-2.4 for PCOS; combined risk haplotype OR 3.1	^[40]^B3b
Type 2 diabetes genetic correlation	rg = 0.12 (BMI-independent); 16 pleiotropic loci	^[237]^B2c
Insulin → AKR1C3	Drives adipose testosterone generation from androstenedione	^[45]^B3b
Type 1 diabetes	PCOS prevalence 24% (95% CI 15-34)	^[31]^A1a
Premature adrenarche	Fasting insulin MD +15.04 pmol/L; forerunner of PCOS	^[77]^B2a

Complications and Long-term Sequelae

▸Women with PCOS have a 1.3- to 1.9-fold increased risk of T2DM, CVD, and all-cause mortality, independent of obesity.
▸Depression (37%) and anxiety (48%) are highly prevalent and are associated with worse outcomes, including increased mortality.
▸Low-dose combined oral contraceptives may reduce dysglycemia and MACE risk, but higher-dose estrogen formulations worsen arterial stiffness.

HY High Yield: Annual screening for depression (PHQ-9) and anxiety (GAD-7) is recommended by the 2023 International PCOS Guideline; these conditions affect 37-48% of women and are linked to increased mortality [2][91].

The genetic and metabolic drivers of PCOS manifest clinically as a spectrum of complications across reproductive, metabolic, and cardiovascular domains, and these accumulate over a woman's lifespan. The 2023 International Evidence-based Guideline recommends that all women with PCOS be screened for type 2 diabetes (T2DM) using an oral glucose tolerance test (OGTT) every 1-3 years, and for cardiovascular risk factors including blood pressure, lipid profile, and smoking status ^[2]^A1c^[9]^A1c. The additional healthcare-related economic burden of PCOS in the United States due to pregnancy-related and long-term morbidities is estimated at $4.3 billion annually (2020 USD) ^[241]^B2a.

Metabolic Consequences

Women with PCOS have a 2- to 3-fold increased risk of impaired glucose tolerance and T2DM compared with age- and BMI-matched controls, independent of obesity ^[94]^D5^[237]^B2c. In a large cohort study, the adjusted hazard ratio for dysglycemia ( or T2DM) in women with PCOS was 1.87 (95% CI 1.78-1.97) ^[127]^B2b. The risk is driven by intrinsic insulin resistance, which is worsened by hyperandrogenism and visceral adiposity ^[82]^C4. reduces fasting insulin and may improve glucose metabolism, but its effect on T2DM incidence is not definitively proven ^[99]^A1a^[246]^A1a. Use of combined (COCPs) in PCOS is associated with a reduced risk of dysglycemia (adjusted odds ratio 0.72, 95%) across all BMI subgroups, a finding that requires further prospective study ^[127]^B2b.

Cardiovascular Disease

Prospective data from three Nordic national cohorts (127,517 women with PCOS) demonstrate a 1.32-fold increased risk of cardiovascular disease (CVD) after adjustment for BMI and education (HR 1.32, 95% CI 1.25-1.39) ^[243]^B2b. The risk persists even in women with BMI <25 kg/m² and no T2DM (HR 1.40, 95% CI 1.26-1.55) ^[243]^B2b. A large US cohort study found that hormonal therapy (including COCPs) initiated within 1 month of diagnosis was associated with lower risk of major adverse cardiovascular events (MACE) (HR 0.72, 95% CI 0.62-0.83) and all-cause mortality (HR 0.68, 95% CI 0.57-0.80) over 1 year, without increased thrombotic risk ^[250]^B3b. However, surrogate markers such as arterial stiffness worsen with higher-dose estrogen preparations, suggesting that a low-dose COCP (≤20 µg ethinyl estradiol) may be preferable in women with additional cardiovascular risk factors ^[70]^A1b. All women with PCOS should undergo annual including blood pressure, lipid panel, and glucose status ^[2]^A1c^[9]^A1c.

Non-Alcoholic Fatty Liver Disease (NAFLD)

NAFLD is a frequent comorbidity in PCOS, driven by insulin resistance and hyperandrogenism ^[245]^D5. The prevalence of NAFLD in PCOS is estimated at 40-60%, significantly higher than in the general population. The fatty liver index and NAFLD fibrosis score are validated surrogate markers for detecting liver damage in this population ^[245]^D5. Lifestyle modification is the cornerstone of ; metformin may improve liver enzymes and histology, and has shown favorable effects on predictors of liver fibrosis in obese PCOS patients ^[44]^D5^[245]^D5.

Obstetric and Offspring Complications

Women with PCOS have higher risks of gestational diabetes (GDM), preeclampsia, preterm birth, and cesarean delivery ^[62]^B2a^[248]^B3b. A multicentre cohort found that gestational lipid profile (elevated triglycerides, low HDL-C) partially mediates the link between PCOS and adverse obstetric outcomes ^[248]^B3b. In women with PCOS undergoing IVF, frozen-embryo transfer reduces the risk of ovarian hyperstimulation syndrome (1.3% vs. 7.1%) and pregnancy loss, but increases the risk of preeclampsia (4.4% vs. 1.4%) compared with fresh-embryo transfer ^[179]^A1b. Metformin use during pregnancy (500 mg twice daily, increasing to 1000 mg twice daily) did not significantly reduce late miscarriage or preterm birth in the PregMet2 trial (OR 0.50) ^[75]^A1b. Offspring of mothers with PCOS show marginally higher total cholesterol levels at 3-6 years of age, although values remain within the normal paediatric range ^[249]^B3b.

Psychiatric Comorbidities

Major depressive disorder (MDD) occurs in 37% (95% CI 29-44%) and anxiety disorders in 48% (95% CI 37-59%) of women with PCOS, based on strong-certainty meta-analytic evidence ^[91]^B2a. Comorbid MDD in PCOS is associated with higher all-cause mortality (RR 1.48, 95% CI 1.4-1.6) and increased risk of dementia (RR 2.1) among diabetic women ^[91]^B2a. The 2023 International Guideline recommends routine screening for depression and anxiety using validated tools (e.g., PHQ-9, GAD-7) at diagnosis and during follow-up ^[2]^A1c^[9]^A1c.

Mortality

In a Finnish cohort with median 12-year follow-up, women with PCOS had increased all-cause mortality (adjusted HR 1.33, 95% CI 1.12-1.59) after adjustment for education, obesity, T2DM, and ^[80]^B3b. Mortality due to neoplasms (HR 1.39) and diseases of the circulatory system (HR 1.68, 95% CI 1.14-2.50) was also elevated ^[80]^B3b. These data underscore the need for long-term surveillance and aggressive risk factor management.

Complication	Approximate Prevalence in PCOS	Key Surveillance/Prevention	Management
Type 2 diabetes	3-10× general population risk	OGTT every 1-3 years	Metformin, lifestyle, consider COCP for dysglycemia risk reduction ^[127]^B2b
Cardiovascular disease	HR 1.32 (95% CI 1.25-1.39)	Annual BP, lipids, glucose; smoking cessation	Low-dose COCP, antihypertensives, as indicated
NAFLD	40-60%	Fatty liver index, NAFLD fibrosis score	Lifestyle, metformin, liraglutide in obese
Gestational diabetes	2-3× risk	Early OGTT in pregnancy	Metformin, insulin if needed
Preeclampsia	1.4-4.4% depending on IVF strategy	prophylaxis if high-risk; monitor BP	Standard obstetric management
MDD	37% (95% CI 29-44%)	PHQ-9 screening	CBT, SSRIs, integrated care
Anxiety	48% (95% CI 37-59%)	GAD-7 screening	CBT, SSRIs
All-cause mortality	HR 1.33 (95% CI 1.12-1.59)	Comprehensive risk factor modification	Multidisciplinary follow-up

Pearl: Screen every woman with PCOS for T2DM, CVD risk, NAFLD, and depression at diagnosis and annually thereafter, the 1.3-fold increased mortality risk is modifiable with early detection and aggressive management of cardiometabolic and psychiatric comorbidities ^[80]^B3b^[91]^B2a^[243]^B2b.

Prognosis, Natural History and Prevention

▸Type 2 diabetes incidence is 4-fold higher in PCOS versus controls, and the risk persists even in lean women (IRR 4.68); screening with OGTT every 2 years is recommended for all women with PCOS.
▸Final BMI after weight loss is the single strongest predictor of PCOS remission, bariatric surgery achieves 78% complete remission versus 15% with medical therapy, and 95% of those with endpoint BMI < 26 kg/m² (surgery) achieve remission.
▸Lifestyle modification (aerobic exercise, combined aerobic+resistance, mind-body exercise) reduces fasting glucose and insulin; yoga is a promising complementary intervention.

HY High Yield: The lipid accumulation product (LAP), calculated from waist circumference and fasting triglycerides, outperforms BMI, waist circumference, and triglycerides alone for screening metabolic syndrome in PCOS (AUROC 0.92, sensitivity 87%, specificity 84%) [140].

! Warning: Do not rely on BMI alone to stratify diabetes risk in PCOS. Lean women with PCOS have a 4.68-fold higher incidence of type 2 diabetes compared with lean controls, making universal OGTT screening essential regardless of weight [81].

These complications arise from a disease trajectory that is established in the peripubertal period and persists across the reproductive lifespan, with metabolic consequences that may worsen after . Without intervention, the natural history of PCOS is one of progressive metabolic deterioration: the incidence of type 2 diabetes is 4.19 per 1,000 person-years in women with PCOS compared with 1.02 per 1,000 person-years in controls (HR 3.23) ^[81]^B2b. This risk is amplified by obesity but remains elevated even in lean women, the incidence rate ratio for type 2 diabetes in healthy-weight PCOS versus controls is 4.68 (P < 0.005) ^[81]^B2b. Cognitive decline and dementia risk are also increased in presence of comorbid diabetes ^[91]^B2a.

Prognostic Factors and Subtypes

Clustering identifies three distinct PCOS subtypes with divergent outcomes: the reproductive subtype (high LH, AMH, total follicle count), the metabolic subtype (high BMI, insulin, LDL, blood pressure), and a background subtype with intermediate features ^[253]^C4. The metabolic subtype carries the highest risk for type 2 diabetes and cardiovascular disease. Final BMI after weight loss is the single strongest predictor of PCOS remission: in a prospective trial, bariatric surgery achieved 78% complete remission versus 15% with plus , and 95% of patients with an endpoint BMI below 26 kg/m² (surgery) or 27.5 kg/m² (drugs) achieved remission ^[4]^B2b.

Prevention Strategies

Lifestyle modification is the cornerstone of prevention. Meta-analysis of 9 RCTs demonstrated that lifestyle intervention reduces fasting blood glucose (weighted mean difference -2.3 mg/dL, 95% CI -4.5 to -0.1) and fasting insulin (WMD -2.1 μU/mL, 95% CI -3.3 to -1.0) compared with minimal intervention ^[252]^A1a. Network meta-analysis ranking exercise modalities shows that aerobic exercise is best for reducing BMI (MD -1.29, 95% CrI -2.39 to -0.21), combined aerobic and resistance exercise for fasting insulin, and mind-body exercise (e.g., yoga) for fasting glucose and HOMA-IR ^[262]^A1a. Yoga also improves anthropometric, endocrine, and psychological outcomes ^[192]^B2a. For women with obesity and PCOS, bariatric surgery should be prioritized because it addresses the primary driver of remission, final BMI ^[4]^B2b. GLP-1 receptor agonists (e.g., ) produce significant weight loss and testosterone reduction, with mixed effects on insulin resistance and menstrual patterns ^[37]^D5.

Screening Recommendations

Type 2 diabetes / impaired glucose tolerance: All women with PCOS should undergo a 2-hour oral glucose tolerance test at diagnosis. If normal, rescreen every 2 years; if impaired glucose tolerance is present, screen annually for progression to diabetes ^[251]^D5. The lipid accumulation product (LAP) is a cost-effective screening tool for metabolic syndrome in PCOS, with a pooled sensitivity of 87% and specificity of 84% (AUROC 0.92) ^[140]^B2a.
: Current guidelines do not recommend routine screening for endometrial hyperplasia or cancer in asymptomatic women with PCOS, despite the increased risk from chronic anovulation ^[239]^D5. Endometrial surveillance is indicated only for abnormal uterine bleeding.
Mental health: Given the 37% prevalence of major depressive disorder and 48% prevalence of anxiety in PCOS ^[91]^B2a, routine screening for depression and anxiety is warranted using validated tools (e.g., PHQ-9, GAD-7).

Family Cascade Screening

PCOS is a highly heritable complex trait, with polygenic influences accounting for approximately 70% of the variance in pathogenesis ^[255]^D5. First-degree female relatives of women with PCOS are at increased risk. Targeted screening of adolescent daughters should be considered if they present with premature adrenarche, low birth weight, intractable obesity with , or atypical sexual precocity, as these are independent prepubertal risk factors ^[255]^D5. However, no formal guideline has yet recommended routine family cascade screening, and the evidence base for its effectiveness remains limited ^[124]^D5.

These preventive strategies and screening protocols are essential to mitigate long-term complications; the of PCOS in the context of pregnancy and fertility is addressed in the following section.

Pearl: Lifestyle modification (aerobic exercise, combined aerobic+resistance, mind-body exercise) reduces fasting glucose and insulin; yoga is a promising complementary intervention.

PCOS Subtypes and Prognostic Implications

Subtype	Key Features	Metabolic Risk
Reproductive	High LH, AMH, total follicle count; high SHBG	Lower
Metabolic	High BMI, insulin, LDL, blood pressure	Highest
Background	Intermediate androstenedione; mixed features	Intermediate

Data from cluster analysis of 2502 women with PCOS ^[253]^C4

Screening Frequency for Metabolic Complications in PCOS

Condition	Screening Test	Frequency	Evidence
Impaired glucose tolerance / Type 2 diabetes	2-hour OGTT	At diagnosis, then every 2 years if normal; annually if IGT	^[251]^D5
Metabolic syndrome	Lipid accumulation product (LAP)	As needed, using fasting lipids and waist circumference	^[140]^B2a
Endometrial hyperplasia	Not routinely recommended	Only for abnormal uterine bleeding	^[239]^D5
Depression, anxiety	PHQ-9, GAD-7	At diagnosis and periodically	^[91]^B2a

Special Populations, Pregnancy and Fertility

▸Letrozole is first-line for ovulation induction in PCOS, with live birth rates 27.5% vs 19.1% for clomiphene (NNT=12).
▸Frozen-embryo transfer in IVF yields higher live birth (49.3% vs 42.0%) and lower OHSS but increases preeclampsia risk.
▸Adolescents require 2 years post-menarche before Rotterdam criteria apply; metformin is preferred over OCP for insulin resistance.

HY High Yield: Letrozole is the first-line ovulation induction agent in PCOS; it outperforms clomiphene in live birth and ovulation rates without increasing twin pregnancy [76].

! Warning: Frozen-embryo transfer in PCOS increases preeclampsia (4.4% vs 1.4%); monitor blood pressure closely in these pregnancies [179].

Building on the natural history of PCOS, clinical must be adapted across the life span, with distinct considerations for pediatrics, pregnancy, the elderly, and immunocompromised hosts.

Pediatrics

Diagnosis in adolescents follows the 2023 International Guideline, which recommends awaiting 2 years post-menarche before applying Rotterdam criteria, as anovulatory cycles and acne are common in early puberty ^[2]^A1c^[9]^A1c. Hyperandrogenism must be confirmed biochemically (elevated free testosterone) rather than by hirsutism scoring alone, which is less reliable in youth ^[2]^A1c. Women born preterm (<34 weeks) have 33% higher testosterone and 64.6% higher free androgen index at age 23 compared with term-born controls, and late-preterm birth carries a 3.1-fold increased odds of PCOS (OR 3.11, 95% CI 1.26-7.70) ^[267]^B2b. is the preferred first-line pharmacotherapy for adolescents with PCOS and insulin resistance, as it improves menstrual regularity without the adverse metabolic effects of , though side effects are more common than in adults (OR 4.76, 95% CI 3.06-7.41) ^[97]^A1a^[196]^A1a. Oral contraceptives may be used for cycle control and hyperandrogenism but should be reserved for those with adequate bone density and no contraindications, as they can worsen metabolic syndrome (OR 2.47) ^[69]^A1b.

Pregnancy and Fertility

Fertility management in PCOS focuses on ovulation induction and pregnancy complication reduction. Letrozole is first-line for ovulation induction: in the landmark RCT, live birth rate was 27.5% vs 19.1% with clomiphene (rate ratio 1.44, 95% CI 1.10-1.87; NNT = 12) ^[76]^A1b. Letrozole also yields higher cumulative ovulation rates (61.7% vs 48.3%) without increased multiple pregnancy ^[24]^A1a^[76]^A1b. For women who fail oral agents, gonadotropins (low-dose step-up protocol) or laparoscopic ovarian drilling are second-line options ^[96]^A1a.

In women with obesity (BMI ≥35 kg/m²), bariatric surgery is highly effective: the BAMBINI trial showed 2.5 times more spontaneous ovulations over 52 weeks vs medical therapy (incidence rate ratio 2.5, 95%) ^[79]^A1b. Complete remission of PCOS (regular menses or spontaneous pregnancy) occurs in 78% of surgical patients vs 15% with drugs (metformin + OCP), with remission dependent on achieving a final BMI below 26-27.5 kg/m² ^[4]^B2b.

For IVF, frozen-embryo transfer is preferred in PCOS: the live birth rate after first transfer is 49.3% vs 42.0% for fresh transfer (rate ratio 1.17, 95% CI 1.05-1.31; NNT = 14), with fewer cases of ovarian hyperstimulation syndrome (OHSS) (1.3% vs 7.1%; NNT = 17) ^[179]^A1b. Preeclampsia risk is higher with frozen transfer (4.4% vs 1.4%; NNH = 33), so blood pressure monitoring is essential ^[179]^A1b.

Metformin during pregnancy reduces late miscarriage and preterm birth: in the PregMet2 trial, the composite outcome occurred in 5% of the metformin group vs 10% of placebo (OR 0.50, 95% CI 0.22-1.08), though not statistically significant ^[75]^A1b. A pooled individual-participant analysis of three trials showed a significant reduction ^[75]^A1b. Metformin does not increase major congenital malformations (RR 0.84, 95% vs insulin) ^[183]^B2b and is safe during ^[2]^A1c.

Gestational diabetes mellitus (GDM) occurs in 25-26% of PCOS pregnancies by week 32, regardless of diagnostic criteria ^[264]^B2b. Pre-meal whey protein (20 g daily) reduces 1-hour postprandial glucose by 20% in early third trimester ^[185]^A1b.

Elderly

After , PCOS features persist with elevated free testosterone, lower SHBG, and increased risk of metabolic syndrome, type 2 diabetes, and cardiovascular disease ^[46]^D5^[268]^D5. The 2023 Guideline recommends screening for glucose intolerance, dyslipidemia, and annually in this population ^[2]^A1c. Hormone therapy is not indicated for PCOS management in menopause; instead, focus on cardiometabolic risk reduction.

Immunocompromised

No specific studies address PCOS management in immunocompromised women. The 2023 Guideline recommends standard diagnostic and treatment algorithms, with caution regarding hormonal therapies that may interact with immunosuppressive regimens (e.g., , ) ^[2]^A1c. Metformin is generally safe, but renal function should be monitored ^[2]^A1c.

Pearl: In PCOS, letrozole is superior to clomiphene for live birth (NNT=12), and frozen-embryo transfer outperforms fresh transfer (NNT=14) but increases preeclampsia risk (NNH=33), counsel patients accordingly.

Controversies and Guideline Disagreement

Question	Position A	Position B	Strength	Implication
First-line ovulation induction	Letrozole (2023 ESE Guideline, ^[2]^A1c)	Clomiphene (older NIH consensus)	Strong for letrozole	Letrozole now standard; clomiphene reserved if letrozole not tolerated
Metformin use in pregnancy	2023 Guideline recommends considering metformin to reduce late miscarriage/preterm birth ^[2]^A1c	Some guidelines (e.g., ACOG) do not recommend routine metformin in PCOS pregnancy	Conditional	Shared decision-making; metformin may be offered after discussion of risks/benefits

Key Fertility Treatments in PCOS

Intervention	Live Birth Rate	NNT	Key Side Effect
Letrozole vs clomiphene ^[76]^A1b	27.5% vs 19.1%	12	Fatigue, dizziness
Frozen vs fresh embryo transfer ^[179]^A1b	49.3% vs 42.0%	14	Preeclampsia (NNH=33)

References

[1]
Azziz R, Carmina E, Dewailly D et al.. “Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline.” The Journal of clinical endocrinology and metabolism (2006). PMID: 16940456 ↗
L1GUIDELINECited in: Definition, Classification and Axis Nomenclature
[2]
Teede HJ, Tay CT, Laven JJE et al.. “Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome.” European journal of endocrinology (2023). PMID: 37580861 ↗
L1GUIDELINECited in: Definition, Classification and Axis Nomenclature, Axis Physiology, Pathophysiology and Biochemical Signature, Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Severity, Staging and Risk Stratification, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment, Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Complications and Long-term Sequelae, Special Populations, Pregnancy and Fertility
[3]
Conway G, Dewailly D, Diamanti-Kandarakis E et al.. “The polycystic ovary syndrome: a position statement from the European Society of Endocrinology.” European journal of endocrinology (2014). PMID: 24849517 ↗
L5GUIDELINECited in: Definition, Classification and Axis Nomenclature, Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment, Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Complications and Long-term Sequelae
[4]
Hu L, Ma L, Xia X et al.. “Efficacy of Bariatric Surgery in the Treatment of Women With Obesity and Polycystic Ovary Syndrome.” The Journal of clinical endocrinology and metabolism (2022). PMID: 35554540 ↗
L2TRIAL_NONRANDOMCited in: Definition, Classification and Axis Nomenclature, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Prognosis, Natural History and Prevention, Special Populations, Pregnancy and Fertility
[5]
Rissetti G, Piovezan JM, Premaor MO et al.. “Contrasting Bone Profiles in PCOS Are Related to BMI: A Systematic Review and Meta-analysis.” The Journal of clinical endocrinology and metabolism (2024). PMID: 38739756 ↗
L1SR_OBSCited in: Definition, Classification and Axis Nomenclature, Severity, Staging and Risk Stratification
[6]
Iliodromiti S, Kelsey TW, Anderson RA et al.. “Can anti-Mullerian hormone predict the diagnosis of polycystic ovary syndrome? A systematic review and meta-analysis of extracted data.” The Journal of clinical endocrinology and metabolism (2013). PMID: 23775353 ↗
L1SR_OBSCited in: Definition, Classification and Axis Nomenclature
[7]
Davitadze M, Malhotra K, Khalil H et al.. “Body image concerns in women with polycystic ovary syndrome: a systematic review and meta-analysis.” European journal of endocrinology (2023). PMID: 37619990 ↗
L1SR_OBSCited in: Definition, Classification and Axis Nomenclature, Severity, Staging and Risk Stratification
[8]
Ollila MM, Arffman RK, Korhonen E et al.. “Women with PCOS have an increased risk for cardiovascular disease regardless of diagnostic criteria-a prospective population-based cohort study.” European journal of endocrinology (2023). PMID: 37436934 ↗
L2COHORTCited in: Definition, Classification and Axis Nomenclature
[9]
Teede HJ, Tay CT, Laven JJE et al.. “Recommendations From the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome.” The Journal of clinical endocrinology and metabolism (2023). PMID: 37580314 ↗
L1OTHERCited in: Definition, Classification and Axis Nomenclature, Axis Physiology, Pathophysiology and Biochemical Signature, Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Severity, Staging and Risk Stratification, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae, Special Populations, Pregnancy and Fertility
[10]
Hoeger KM, Dokras A, Piltonen T. “Update on PCOS: Consequences, Challenges, and Guiding Treatment.” The Journal of clinical endocrinology and metabolism (2021). PMID: 33211867 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Axis Nomenclature, Axis Physiology, Pathophysiology and Biochemical Signature, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
[11]
Vale-Fernandes E, Pignatelli D, Monteiro MP. “Should anti-Müllerian hormone be a diagnosis criterion for polycystic ovary syndrome? An in-depth review of pros and cons.” European journal of endocrinology (2025). PMID: 40186490 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Axis Nomenclature, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
[12]
Kiconco S, Earnest A, Enticott J et al.. “Normative cut-offs for polycystic ovary syndrome diagnostic features in adolescents using cluster analysis.” European journal of endocrinology (2023). PMID: 37243570 ↗
L4OTHERCited in: Definition, Classification and Axis Nomenclature
[13]
Joham AE, Norman RJ, Stener-Victorin E et al.. “Polycystic ovary syndrome.” The lancet. Diabetes & endocrinology (2022). PMID: 35934017 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Axis Nomenclature, Axis Physiology, Pathophysiology and Biochemical Signature, Clinical Presentation, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Complications and Long-term Sequelae
[14]
Teede HJ, Khomami MB, Morman R et al.. “Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: a multistep global consensus process.” Lancet (London, England) (2026). PMID: 42119588 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Axis Nomenclature, Axis Physiology, Pathophysiology and Biochemical Signature, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Severity, Staging and Risk Stratification, History and Evolution of Treatment, Multiglandular Syndromes, Genetic Context and Co-Axis Effects
[15]
Norman RJ, Dewailly D, Legro RS et al.. “Polycystic ovary syndrome.” Lancet (London, England) (2007). PMID: 17720020 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Axis Nomenclature, Epidemiology, Etiology and Risk Factors, Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Complications and Long-term Sequelae
[16]
Jiang M, Wang T, Huang L. “Serum vitamin D levels in non-obese women with polycystic ovary syndrome: a systematic review and meta-analysis.” Frontiers in endocrinology (2026). PMID: 42381874 ↗
L1SR_OBSCited in: Definition, Classification and Axis Nomenclature, Multiglandular Syndromes, Genetic Context and Co-Axis Effects
[17]
Güner Emül T, Kaplan Serin E. “The Relationship Between 2D:4D Digit Ratio and Polycystic Ovary Syndrome: A Systematic Review.” American journal of human biology : the official journal of the Human Biology Council (2026). PMID: 42249717 ↗
L3SR_OBSCited in: Definition, Classification and Axis Nomenclature, Prognosis, Natural History and Prevention
[18]
Fernando SPW, Ramdass PVAK. “Adiponectin and Polycystic Ovary Syndrome in Adolescent Girls: A Systematic Review and Meta-Analysis.” International journal of molecular sciences (2026). PMID: 42123535 ↗
L1SR_OBSCited in: Definition, Classification and Axis Nomenclature
[19]
Cao Q, Du S, Li Z et al.. “Neuropsychiatric disorders in children of mothers with polycystic ovary syndrome: a systematic review and meta-analysis.” BMC psychiatry (2026). PMID: 41935305 ↗
L1SR_OBSCited in: Definition, Classification and Axis Nomenclature
[20]
Palomba S, Costanzi F, Seminara G et al.. “Is polycystic ovary syndrome associated with uterine malformations? A systematic review using Bradford Hill's causality framework.” Human reproduction open (2026). PMID: 41696680 ↗
L3SR_OBSCited in: Definition, Classification and Axis Nomenclature
[21]
Dumont T, Peeva M, El Masri M. “Diagnosis and treatment of PCOS in adolescents: a summary of guidelines and systematic reviews for practitioners.” Best practice & research. Clinical obstetrics & gynaecology (2026). PMID: 41616460 ↗
L5SR_OBSCited in: Definition, Classification and Axis Nomenclature
[22]
Dapas M, Dunaif A. “Deconstructing a Syndrome: Genomic Insights Into PCOS Causal Mechanisms and Classification.” Endocrine reviews (2022). PMID: 35026001 ↗
L5OTHERCited in: Definition, Classification and Axis Nomenclature, Epidemiology, Etiology and Risk Factors, Severity, Staging and Risk Stratification, Multiglandular Syndromes, Genetic Context and Co-Axis Effects
[23]
Dumesic DA, Oberfield SE, Stener-Victorin E et al.. “Scientific Statement on the Diagnostic Criteria, Epidemiology, Pathophysiology, and Molecular Genetics of Polycystic Ovary Syndrome.” Endocrine reviews (2015). PMID: 26426951 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Axis Nomenclature, Axis Physiology, Pathophysiology and Biochemical Signature, Epidemiology, Etiology and Risk Factors, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
[24]
Franik S, Le QK, Kremer JA et al.. “Aromatase inhibitors (letrozole) for ovulation induction in infertile women with polycystic ovary syndrome.” The Cochrane database of systematic reviews (2022). PMID: 36165742 ↗
L1SR_OBSCited in: Definition, Classification and Axis Nomenclature, Axis Physiology, Pathophysiology and Biochemical Signature, Severity, Staging and Risk Stratification, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Special Populations, Pregnancy and Fertility
[25]
Tang T, Lord JM, Norman RJ et al.. “Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility.” The Cochrane database of systematic reviews (2010). PMID: 20091537 ↗
L1SR_OBSCited in: Definition, Classification and Axis Nomenclature, Severity, Staging and Risk Stratification
[26]
Tang T, Lord JM, Norman RJ et al.. “Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility.” The Cochrane database of systematic reviews (2009). PMID: 19821299 ↗
L1SR_OBSCited in: Definition, Classification and Axis Nomenclature, Severity, Staging and Risk Stratification
[27]
Elkind-Hirsch KE, Chappell N, Seidemann E et al.. “Exenatide, Dapagliflozin, or Phentermine/Topiramate Differentially Affect Metabolic Profiles in Polycystic Ovary Syndrome.” The Journal of clinical endocrinology and metabolism (2021). PMID: 34097062 ↗
L1RCTCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment
[28]
Jensterle Sever M, Kocjan T, Pfeifer M et al.. “Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin.” European journal of endocrinology (2014). PMID: 24362411 ↗
L1RCTCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Severity, Staging and Risk Stratification, History and Evolution of Treatment
[29]
Bril F, Ezeh U, Amiri M et al.. “Adipose Tissue Dysfunction in Polycystic Ovary Syndrome.” The Journal of clinical endocrinology and metabolism (2023). PMID: 37329216 ↗
L2SR_OBSCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Multiglandular Syndromes, Genetic Context and Co-Axis Effects
[30]
Codner E, Escobar-Morreale HF. “Clinical review: Hyperandrogenism and polycystic ovary syndrome in women with type 1 diabetes mellitus.” The Journal of clinical endocrinology and metabolism (2007). PMID: 17284617 ↗
L5SR_OBSCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Complications and Long-term Sequelae
[31]
Escobar-Morreale HF, Roldán-Martín MB. “Type 1 Diabetes and Polycystic Ovary Syndrome: Systematic Review and Meta-analysis.” Diabetes care (2016). PMID: 27208367 ↗
L1SR_OBSCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Complications and Long-term Sequelae, Prognosis, Natural History and Prevention
[32]
Studen KB, Sebestjen M, Pfeifer M et al.. “Influence of spironolactone treatment on endothelial function in non-obese women with polycystic ovary syndrome.” European journal of endocrinology (2010). PMID: 21156647 ↗
L2TRIAL_NONRANDOMCited in: Axis Physiology, Pathophysiology and Biochemical Signature
[33]
Forslund M, Wändell P, Forsberg L et al.. “GLP-1 receptor agonist treatment in women with polycystic ovary syndrome-a systematic review and meta-analysis.” European journal of endocrinology (2026). PMID: 41701618 ↗
L1SR_OBSCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Multiglandular Syndromes, Genetic Context and Co-Axis Effects
[34]
Lerchbaum E, Obermayer-Pietsch B. “Vitamin D and fertility: a systematic review.” European journal of endocrinology (2012). PMID: 22275473 ↗
L2SR_OBSCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae, Special Populations, Pregnancy and Fertility
[35]
Krul-Poel YH, Snackey C, Louwers Y et al.. “The role of vitamin D in metabolic disturbances in polycystic ovary syndrome: a systematic review.” European journal of endocrinology (2013). PMID: 24044903 ↗
L2SR_OBSCited in: Axis Physiology, Pathophysiology and Biochemical Signature
[36]
Gambineri A, Semple RK, Forlani G et al.. “Monogenic polycystic ovary syndrome due to a mutation in the lamin A/C gene is sensitive to thiazolidinediones but not to metformin.” European journal of endocrinology (2008). PMID: 18728124 ↗
L4CASE_REPORTCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Clinical Presentation, Prognosis, Natural History and Prevention
[37]
Cena H, Chiovato L, Nappi RE. “Obesity, Polycystic Ovary Syndrome, and Infertility: A New Avenue for GLP-1 Receptor Agonists.” The Journal of clinical endocrinology and metabolism (2020). PMID: 32442310 ↗
L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature, Severity, Staging and Risk Stratification, Prognosis, Natural History and Prevention, Special Populations, Pregnancy and Fertility
[38]
Azziz R, Amiri M, Bril F et al.. “Approach to the Patient: Hirsutism.” The Journal of clinical endocrinology and metabolism (2025). PMID: 40200552 ↗
L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature
[39]
Zhu T, Goodarzi MO. “Causes and Consequences of Polycystic Ovary Syndrome: Insights From Mendelian Randomization.” The Journal of clinical endocrinology and metabolism (2022). PMID: 34669940 ↗
L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature, Complications and Long-term Sequelae
[40]
Goodarzi MO, Jones MR, Chen YD et al.. “First evidence of genetic association between AKT2 and polycystic ovary syndrome.” Diabetes care (2008). PMID: 18768676 ↗
L3OTHERCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Prognosis, Natural History and Prevention
[41]
Beckman JA, Goldfine AB, Dunaif A et al.. “Endothelial function varies according to insulin resistance disease type.” Diabetes care (2007). PMID: 17261751 ↗
L4OTHERCited in: Axis Physiology, Pathophysiology and Biochemical Signature
[42]
Gosseaume C, Fournier T, Jéru I et al.. “Perinatal, metabolic, and reproductive features in PPARG-related lipodystrophy.” European journal of endocrinology (2023). PMID: 36806620 ↗
L4OTHERCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Acute Management and Endocrine Emergencies
[43]
Jobanputra R, Sargeant JA, Plekhanova T et al.. “The Effects of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Co-Transporter-2 Inhibitors on Lean Body Mass in Humans: A Systematic Review and Meta-Analysis of Randomised Controlled Trials.” Diabetes/metabolism research and reviews (2026). PMID: 42319968 ↗
L1SR_MA_RCTCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
[44]
Savas M, Kuckuck S, Boon MR et al.. “Beyond weight loss: multisystem benefits of obesity medications.” The lancet. Diabetes & endocrinology (2026). PMID: 42208956 ↗
L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature, Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Complications and Long-term Sequelae
[45]
O'Reilly M, Gathercole L, Capper F et al.. “Effect of insulin on AKR1C3 expression in female adipose tissue: in-vivo and in-vitro study of adipose androgen generation in polycystic ovary syndrome.” Lancet (London, England) (2015). PMID: 26312838 ↗
L3OTHERCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Multiglandular Syndromes, Genetic Context and Co-Axis Effects
[46]
Stener-Victorin E, Carlsson S, Hagström H et al.. “MASLD, diabetes and PMOS across the female life stages.” Diabetologia (2026). PMID: 42249186 ↗
L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature, Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Prognosis, Natural History and Prevention, Special Populations, Pregnancy and Fertility
[47]
Meier JJ, Nauck MA. “Incretin-based therapies: where will we be 50 years from now?” Diabetologia (2015). PMID: 25994073 ↗
L5OTHERCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Multiglandular Syndromes, Genetic Context and Co-Axis Effects
[48]
Sam S, Ehrmann DA. “Metformin therapy for the reproductive and metabolic consequences of polycystic ovary syndrome.” Diabetologia (2017). PMID: 28770330 ↗
L5OTHERCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Multiglandular Syndromes, Genetic Context and Co-Axis Effects
[49]
Tan BK, Chen J, Digby JE et al.. “Upregulation of adiponectin receptor 1 and 2 mRNA and protein in adipose tissue and adipocytes in insulin-resistant women with polycystic ovary syndrome.” Diabetologia (2006). PMID: 17001470 ↗
L3OTHERCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
[50]
Diamanti-Kandarakis E, Dunaif A. “Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications.” Endocrine reviews (2012). PMID: 23065822 ↗
L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Multiglandular Syndromes, Genetic Context and Co-Axis Effects
[51]
di Clemente N, Racine C, Pierre A et al.. “Anti-Müllerian Hormone in Female Reproduction.” Endocrine reviews (2021). PMID: 33851994 ↗
L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature, Multiglandular Syndromes, Genetic Context and Co-Axis Effects
[52]
Hsueh AJ, Kawamura K, Cheng Y et al.. “Intraovarian control of early folliculogenesis.” Endocrine reviews (2014). PMID: 25202833 ↗
L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Multiglandular Syndromes, Genetic Context and Co-Axis Effects
[53]
Stener-Victorin E, Padmanabhan V, Walters KA et al.. “Animal Models to Understand the Etiology and Pathophysiology of Polycystic Ovary Syndrome.” Endocrine reviews (2020). PMID: 32310267 ↗
L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature, Epidemiology, Etiology and Risk Factors, Prognosis, Natural History and Prevention
[54]
Anderson RC, Newton CL, Anderson RA et al.. “Gonadotropins and Their Analogs: Current and Potential Clinical Applications.” Endocrine reviews (2018). PMID: 29982442 ↗
L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Prognosis, Natural History and Prevention, Special Populations, Pregnancy and Fertility
[55]
El Dib R, Gameiro OL, Ogata MS et al.. “Zinc supplementation for the prevention of type 2 diabetes mellitus in adults with insulin resistance.” The Cochrane database of systematic reviews (2015). PMID: 26020622 ↗
L1SR_OBSCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Complications and Long-term Sequelae, Prognosis, Natural History and Prevention
[56]
Franik S, Eltrop SM, Kremer JA et al.. “Aromatase inhibitors (letrozole) for subfertile women with polycystic ovary syndrome.” The Cochrane database of systematic reviews (2018). PMID: 29797697 ↗
L1SR_OBSCited in: Axis Physiology, Pathophysiology and Biochemical Signature
[57]
Meza N, Bracchiglione J, Escobar Liquitay CM et al.. “Liraglutide for adults living with obesity.” The Cochrane database of systematic reviews (2025). PMID: 41161684 ↗
L1SR_OBSCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Complications and Long-term Sequelae
[58]
Beletate V, El Dib RP, Atallah AN. “Zinc supplementation for the prevention of type 2 diabetes mellitus.” The Cochrane database of systematic reviews (2007). PMID: 17253560 ↗
L1SR_OBSCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Complications and Long-term Sequelae, Prognosis, Natural History and Prevention
[59]
Skalkidou A, Sergentanis TN, Gialamas SP et al.. “Risk of endometrial cancer in women treated with ovary-stimulating drugs for subfertility.” The Cochrane database of systematic reviews (2017). PMID: 28349511 ↗
L2SR_OBSCited in: Axis Physiology, Pathophysiology and Biochemical Signature
[60]
Dziewierz A, Kulicka N, Stolarska K et al.. “Temporal Trends and Clinical Characteristics of Incretin-Based Therapy Use in Women With Polycystic Ovary Syndrome: A Real-World Cohort Study From a Polish Private Healthcare Network.” Diabetes, obesity & metabolism (2026). PMID: 42297761 ↗
L2COHORTCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
[61]
Zhao Z. “Associations between serum persistent organic pollutants and polycystic ovary syndrome risk: a case-control study with mediation analysis.” Frontiers in public health (2026). PMID: 42338522 ↗
L3CASE_CONTROLCited in: Axis Physiology, Pathophysiology and Biochemical Signature
[62]
Odunvbun WO, Ukoba O, Isogun JK et al.. “A systematic review of pregnancy outcomes and management in polycystic ovary syndrome.” African journal of reproductive health (2026). PMID: 42202883 ↗
L2SR_OBSCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Complications and Long-term Sequelae
[63]
Ji C, Zheng X, Wang Q et al.. “A Case Report: Treatment, follow-up, and literature review of type A insulin resistance syndrome caused by a De Novo INSR c.3328G>C mutation.” Frontiers in endocrinology (2026). PMID: 42272804 ↗
L4CASE_REPORTCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae
[64]
Javed M, Suramya S, Javed H et al.. “A Review of microRNAs in the Post-transcriptional Regulation and its Clinical Manifestation in the Polycystic Ovary Syndrome.” Reproductive sciences (Thousand Oaks, Calif.) (2026). PMID: 42426428 ↗
L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature
[65]
Juneja S, Bhati BS. “MedFusionNet: A hybrid transformer-based multimodal deep learning framework for chronic disease prediction in women's health.” Computerized medical imaging and graphics : the official journal of the Computerized Medical Imaging Society (2026). PMID: 42424829 ↗
L5OTHERCited in: Axis Physiology, Pathophysiology and Biochemical Signature
[66]
Hu R, Li F, Dong H et al.. “Kuntai capsule ameliorates PCOS by reversing tryptophan metabolic shift and aberrant nuclear AHR activation: a multi-omics investigation.” Phytomedicine : international journal of phytotherapy and phytopharmacology (2026). PMID: 42398205 ↗
L4OTHERCited in: Axis Physiology, Pathophysiology and Biochemical Signature
[67]
Legro RS, Arslanian SA, Ehrmann DA et al.. “Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline.” The Journal of clinical endocrinology and metabolism (2013). PMID: 24151290 ↗
L1GUIDELINECited in: Epidemiology, Etiology and Risk Factors, Clinical Presentation, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Severity, Staging and Risk Stratification, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment, Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Complications and Long-term Sequelae
[68]
Eisenberg E, Legro RS, Diamond MP et al.. “Sleep Habits of Women With Infertility.” The Journal of clinical endocrinology and metabolism (2021). PMID: 34180998 ↗
L2RCTCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment, Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Special Populations, Pregnancy and Fertility
[69]
Legro RS, Dodson WC, Kris-Etherton PM et al.. “Randomized Controlled Trial of Preconception Interventions in Infertile Women With Polycystic Ovary Syndrome.” The Journal of clinical endocrinology and metabolism (2015). PMID: 26401593 ↗
L1RCTCited in: Epidemiology, Etiology and Risk Factors, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment, Special Populations, Pregnancy and Fertility
[70]
Meyer C, McGrath BP, Teede HJ. “Effects of medical therapy on insulin resistance and the cardiovascular system in polycystic ovary syndrome.” Diabetes care (2007). PMID: 17327307 ↗
L1RCTCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment, Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Complications and Long-term Sequelae
[71]
Dietz de Loos A, Jiskoot G, Beerthuizen A et al.. “Metabolic health during a randomized controlled lifestyle intervention in women with PCOS.” European journal of endocrinology (2021). PMID: 34714771 ↗
L1RCTCited in: Epidemiology, Etiology and Risk Factors, Severity, Staging and Risk Stratification, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment, Multiglandular Syndromes, Genetic Context and Co-Axis Effects
[72]
Amiri M, Hatoum S, Hopkins D et al.. “The Association Between Obesity and Polycystic Ovary Syndrome: An Epidemiologic Study of Observational Data.” The Journal of clinical endocrinology and metabolism (2024). PMID: 39078989 ↗
L2SR_OBSCited in: Epidemiology, Etiology and Risk Factors
[73]
Cooney LG, Gyorfi K, Sanneh A et al.. “Increased Prevalence of Binge Eating Disorder and Bulimia Nervosa in Women With Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis.” The Journal of clinical endocrinology and metabolism (2024). PMID: 39115340 ↗
L2SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Severity, Staging and Risk Stratification
[74]
Pace L, Markovic D, Buyalos R et al.. “Economic Burden of Endometrial Cancer Associated With Polycystic Ovary Syndrome.” The Journal of clinical endocrinology and metabolism (2024). PMID: 39106216 ↗
L2SR_OBSCited in: Epidemiology, Etiology and Risk Factors
[75]
Løvvik TS, Carlsen SM, Salvesen Ø et al.. “Use of metformin to treat pregnant women with polycystic ovary syndrome (PregMet2): a randomised, double-blind, placebo-controlled trial.” The lancet. Diabetes & endocrinology (2019). PMID: 30792154 ↗
L1RCTCited in: Epidemiology, Etiology and Risk Factors, Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment, Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Complications and Long-term Sequelae, Special Populations, Pregnancy and Fertility
[76]
Legro RS, Brzyski RG, Diamond MP et al.. “Letrozole versus clomiphene for infertility in the polycystic ovary syndrome.” The New England journal of medicine (2014). PMID: 25006718 ↗
L1RCTCited in: Epidemiology, Etiology and Risk Factors, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment, Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Special Populations, Pregnancy and Fertility
[77]
Ben Said W, Lempesis IG, Fernandez-Garcia S et al.. “Premature adrenarche and metabolic risk: a systematic review and meta-analysis.” European journal of endocrinology (2025). PMID: 40884153 ↗
L2SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Clinical Presentation, Multiglandular Syndromes, Genetic Context and Co-Axis Effects
[78]
Neven ACH, Forslund M, Ranashinha S et al.. “Prevalence and accurate diagnosis of polycystic ovary syndrome in adolescents across world regions: a systematic review and meta-analysis.” European journal of endocrinology (2024). PMID: 39353075 ↗
L2SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
[79]
Samarasinghe SNS, Leca B, Alabdulkader S et al.. “Bariatric surgery for spontaneous ovulation in women living with polycystic ovary syndrome: the BAMBINI multicentre, open-label, randomised controlled trial.” Lancet (London, England) (2024). PMID: 38782004 ↗
L1RCTCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment, Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Complications and Long-term Sequelae, Special Populations, Pregnancy and Fertility
[80]
Piltonen TT, Koskenkari N, Koivuaho E et al.. “Increased mortality in polycystic ovary syndrome- a cohort study.” European journal of endocrinology (2026). PMID: 42213411 ↗
L3COHORTCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Complications and Long-term Sequelae
[81]
Kakoly NS, Earnest A, Teede HJ et al.. “The Impact of Obesity on the Incidence of Type 2 Diabetes Among Women With Polycystic Ovary Syndrome.” Diabetes care (2019). PMID: 30705063 ↗
L2OTHERCited in: Epidemiology, Etiology and Risk Factors, History and Evolution of Treatment, Prognosis, Natural History and Prevention
[82]
Karakas SE, Kim K, Duleba AJ. “Determinants of impaired fasting glucose versus glucose intolerance in polycystic ovary syndrome.” Diabetes care (2010). PMID: 20067969 ↗
L4OTHERCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Complications and Long-term Sequelae
[83]
Palomba S, Falbo A, Russo T et al.. “The risk of a persistent glucose metabolism impairment after gestational diabetes mellitus is increased in patients with polycystic ovary syndrome.” Diabetes care (2012). PMID: 22338097 ↗
L3OTHERCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
[84]
Gaberšček S, Zaletel K, Schwetz V et al.. “Mechanisms in endocrinology: thyroid and polycystic ovary syndrome.” European journal of endocrinology (2015). PMID: 25422352 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology and Risk Factors
[85]
Guo S, Xia H, Yang W et al.. “Clinical efficacy of acupuncture for women with PCOS undergoing IVF/ICSI: a meta-analysis of randomized controlled trials.” Frontiers in endocrinology (2026). PMID: 42290862 ↗
L1SR_MA_RCTCited in: Epidemiology, Etiology and Risk Factors, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Special Populations, Pregnancy and Fertility
[86]
Thong EP, Codner E, Laven JSE et al.. “Diabetes: a metabolic and reproductive disorder in women.” The lancet. Diabetes & endocrinology (2019). PMID: 31635966 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Special Populations, Pregnancy and Fertility
[87]
Schoonejans JM, Blackmore HL, Ashmore TJ et al.. “Sex-specific effects of maternal metformin intervention during glucose-intolerant obese pregnancy on body composition and metabolic health in aged mouse offspring.” Diabetologia (2022). PMID: 36112170 ↗
L5OTHERCited in: Epidemiology, Etiology and Risk Factors, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Special Populations, Pregnancy and Fertility
[88]
Baillargeon JP, Carpentier AC. “Brothers of women with polycystic ovary syndrome are characterised by impaired glucose tolerance, reduced insulin sensitivity and related metabolic defects.” Diabetologia (2007). PMID: 17898989 ↗
L3OTHERCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
[89]
Barber TM, Bennett AJ, Groves CJ et al.. “Association of variants in the fat mass and obesity associated (FTO) gene with polycystic ovary syndrome.” Diabetologia (2008). PMID: 18478198 ↗
L3OTHERCited in: Epidemiology, Etiology and Risk Factors
[90]
Barber TM, Bennett AJ, Groves CJ et al.. “Disparate genetic influences on polycystic ovary syndrome (PCOS) and type 2 diabetes revealed by a lack of association between common variants within the TCF7L2 gene and PCOS.” Diabetologia (2007). PMID: 17805508 ↗
L3OTHERCited in: Epidemiology, Etiology and Risk Factors
[91]
Fornaro M, Di Lorenzo C, Steardo L et al.. “Prevalence and outcomes of co-occurring psychiatric and endocrine, metabolic, and nutritional disorders: An atlas based on umbrella review of 254,154,533 records.” European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology (2026). PMID: 42217371 ↗
L2SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Severity, Staging and Risk Stratification, Complications and Long-term Sequelae, Prognosis, Natural History and Prevention
[92]
Stańczyk K, Łopacińska O, Kędzia D et al.. “Depressive and Anxiety Symptoms in Women with Polycystic Ovary Syndrome: A Meta-Analysis.” Journal of clinical medicine (2026). PMID: 42194542 ↗
L4SR_OBSCited in: Epidemiology, Etiology and Risk Factors
[93]
Eng PC, Phylactou M, Qayum A et al.. “Obesity-Related Hypogonadism in Women.” Endocrine reviews (2024). PMID: 37559411 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology and Risk Factors, Multiglandular Syndromes, Genetic Context and Co-Axis Effects
[94]
Randeva HS, Tan BK, Weickert MO et al.. “Cardiometabolic aspects of the polycystic ovary syndrome.” Endocrine reviews (2012). PMID: 22829562 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology and Risk Factors, Complications and Long-term Sequelae
[95]
Tso LO, Costello MF, Albuquerque LET et al.. “Metformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome.” The Cochrane database of systematic reviews (2020). PMID: 33347618 ↗
L1SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Special Populations, Pregnancy and Fertility
[96]
Weiss NS, Kostova EB, Mol BWJ et al.. “Gonadotropins for ovulation induction in women with polycystic ovary syndrome.” The Cochrane database of systematic reviews (2025). PMID: 40193219 ↗
L1SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Complications and Long-term Sequelae, Special Populations, Pregnancy and Fertility
[97]
Fraison E, Kostova E, Moran LJ et al.. “Metformin versus the combined oral contraceptive pill for hirsutism, acne, and menstrual pattern in polycystic ovary syndrome.” The Cochrane database of systematic reviews (2020). PMID: 32794179 ↗
L1SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Special Populations, Pregnancy and Fertility
[98]
Zhuang J, Wang X, Xu L et al.. “Antidepressants for polycystic ovary syndrome.” The Cochrane database of systematic reviews (2013). PMID: 23728677 ↗
L1SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Multiglandular Syndromes, Genetic Context and Co-Axis Effects
[99]
Tang T, Lord JM, Norman RJ et al.. “WITHDRAWN: Insulin-sensitising drugs for polycystic ovary syndrome.” The Cochrane database of systematic reviews (2009). PMID: 19588338 ↗
L1SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment, Complications and Long-term Sequelae, Special Populations, Pregnancy and Fertility
[100]
Tso LO, Costello MF, Albuquerque LE et al.. “Metformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome.” The Cochrane database of systematic reviews (2014). PMID: 25406011 ↗
L1SR_OBSCited in: Epidemiology, Etiology and Risk Factors
[101]
Weiss NS, Kostova E, Nahuis M et al.. “Gonadotrophins for ovulation induction in women with polycystic ovary syndrome.” The Cochrane database of systematic reviews (2019). PMID: 30648738 ↗
L1SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
[102]
Han Q, Li M, Li G et al.. “A nomogram to predict early spontaneous abortion in women with polycystic ovary syndrome: a retrospective cohort study.” BMC pregnancy and childbirth (2026). PMID: 42432589 ↗
L2COHORTCited in: Epidemiology, Etiology and Risk Factors, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Special Populations, Pregnancy and Fertility
[103]
Lee SH, Lee KS, Lee JY et al.. “Impact of gestational diabetes on future diabetic retinopathy and microvascular complications: a nationwide cohort study.” BMC medicine (2026). PMID: 42399945 ↗
L2COHORTCited in: Epidemiology, Etiology and Risk Factors, History and Evolution of Treatment, Complications and Long-term Sequelae
[104]
Sung J, Chang R, Chen SN et al.. “Obstructive Sleep Apnea and Risk for Thromboembolic Complication Among Patients With Polycystic Ovary Syndrome: A Retrospective Cohort Study.” BJOG : an international journal of obstetrics and gynaecology (2026). PMID: 42248807 ↗
L2COHORTCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
[105]
Machado IFR, Tinano FR, Latronico AC et al.. “Approach to the diagnosis and treatment of polycystic ovarian syndrome in adolescent patients.” The Journal of clinical endocrinology and metabolism (2026). PMID: 42105324 ↗
L5OTHERCited in: Clinical Presentation
[106]
Franks S. “Controversy in clinical endocrinology: diagnosis of polycystic ovarian syndrome: in defense of the Rotterdam criteria.” The Journal of clinical endocrinology and metabolism (2006). PMID: 16418209 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation
[107]
Actkins KV, Singh K, Hucks D et al.. “Characterizing the Clinical and Genetic Spectrum of Polycystic Ovary Syndrome in Electronic Health Records.” The Journal of clinical endocrinology and metabolism (2021). PMID: 32961557 ↗
L4OTHERCited in: Clinical Presentation
[108]
Suturina L, Lizneva D, Lazareva L et al.. “Ethnicity and the Prevalence of Polycystic Ovary Syndrome: The Eastern Siberia PCOS Epidemiology and Phenotype Study.” The Journal of clinical endocrinology and metabolism (2024). PMID: 38888252 ↗
L4OTHERCited in: Clinical Presentation
[109]
Yildiz BO, Knochenhauer ES, Azziz R. “Impact of obesity on the risk for polycystic ovary syndrome.” The Journal of clinical endocrinology and metabolism (2007). PMID: 17925334 ↗
L4OTHERCited in: Clinical Presentation
[110]
Santoro N. “Update in hyper- and hypogonadotropic amenorrhea.” The Journal of clinical endocrinology and metabolism (2011). PMID: 22058375 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation
[111]
Broughton S, Armeni E, Chu A et al.. “The association between body image and well-being in polycystic ovary syndrome: a mixed-methods study.” European journal of endocrinology (2026). PMID: 41656064 ↗
L4OTHERCited in: Clinical Presentation, Severity, Staging and Risk Stratification
[112]
Romero-Ruiz A, Pineda B, Ovelleiro D et al.. “Molecular diagnosis of polycystic ovary syndrome in obese and non-obese women by targeted plasma miRNA profiling.” European journal of endocrinology (2021). PMID: 34403358 ↗
L3OTHERCited in: Clinical Presentation
[113]
Barth JH, Field HP, Yasmin E et al.. “Defining hyperandrogenism in polycystic ovary syndrome: measurement of testosterone and androstenedione by liquid chromatography-tandem mass spectrometry and analysis by receiver operator characteristic plots.” European journal of endocrinology (2009). PMID: 20008514 ↗
L4OTHERCited in: Clinical Presentation
[114]
McCartney CR, Marshall JC. “CLINICAL PRACTICE. Polycystic Ovary Syndrome.” The New England journal of medicine (2016). PMID: 27406348 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation, Multiglandular Syndromes, Genetic Context and Co-Axis Effects
[115]
Lu F, Yu H, Feng J et al.. “The impact of age on clinical features and fertility outcomes in patients with polycystic ovary syndrome: a secondary analysis based on the PCOSAct trial.” Frontiers in endocrinology (2026). PMID: 41625240 ↗
L2RCTCited in: Clinical Presentation
[116]
Chauhan S, Muka T, Najaf SS et al.. “Effects of yoga interventions on Anti-Müllerian hormone, androgen levels, and metabolic parameters in women with polycystic ovary syndrome: a systematic review.” BMC complementary medicine and therapies (2026). PMID: 41782111 ↗
L1SR_OBSCited in: Clinical Presentation
[117]
Ghaderzadeh M, Garavand A, Salehnasab C. “Artificial intelligence in polycystic ovary syndrome: a systematic review of diagnostic and predictive applications.” BMC medical informatics and decision making (2025). PMID: 41286838 ↗
L3SR_OBSCited in: Clinical Presentation
[118]
Lim SS, Hutchison SK, Van Ryswyk E et al.. “Lifestyle changes in women with polycystic ovary syndrome.” The Cochrane database of systematic reviews (2019). PMID: 30921477 ↗
L1SR_OBSCited in: Clinical Presentation, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Prognosis, Natural History and Prevention, Special Populations, Pregnancy and Fertility
[119]
Moran LJ, Hutchison SK, Norman RJ et al.. “Lifestyle changes in women with polycystic ovary syndrome.” The Cochrane database of systematic reviews (2011). PMID: 21328294 ↗
L1SR_OBSCited in: Clinical Presentation, Prognosis, Natural History and Prevention
[120]
Moran LJ, Hutchison SK, Norman RJ et al.. “Lifestyle changes in women with polycystic ovary syndrome.” The Cochrane database of systematic reviews (2011). PMID: 21735412 ↗
L1SR_OBSCited in: Clinical Presentation, Prognosis, Natural History and Prevention
[121]
Ibibama JO, Madaki PD, Aliche KA et al.. “Environmental Toxicants and Polycystic Ovary Syndrome: Implications for a Metabolic-Ovarian Framework (PMOS) - A Systematic Review.” Biological trace element research (2026). PMID: 42426543 ↗
L2SR_OBSCited in: Clinical Presentation
[122]
Atinga A, Bashiru HA, Solomon AO et al.. “Depression and anxiety among women with polycystic ovarian syndrome in low- and middle-income countries: a systematic review and meta-analysis.” Frontiers in global women's health (2025). PMID: 41378340 ↗
L2SR_OBSCited in: Clinical Presentation
[123]
. “[Guidelines for the diagnosis and treatment of obstructive sleep apnea in adults (2025)].” Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases (2026). PMID: 41820035 ↗
L1GUIDELINECited in: Clinical Presentation, Severity, Staging and Risk Stratification, History and Evolution of Treatment
[124]
Al Wattar BH, Fisher M, Bevington L et al.. “Clinical Practice Guidelines on the Diagnosis and Management of Polycystic Ovary Syndrome: A Systematic Review and Quality Assessment Study.” The Journal of clinical endocrinology and metabolism (2021). PMID: 33839790 ↗
L5GUIDELINECited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Complications and Long-term Sequelae, Prognosis, Natural History and Prevention
[125]
Jensterle M, Kovac J, Vovk A et al.. “Semaglutide and Taste in Women With Obesity and Polycystic Ovary Syndrome: A Randomized Placebo-Controlled Study.” The Journal of clinical endocrinology and metabolism (2025). PMID: 40341357 ↗
L1RCTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment
[126]
Hutchison SK, Harrison C, Stepto N et al.. “Retinol-binding protein 4 and insulin resistance in polycystic ovary syndrome.” Diabetes care (2008). PMID: 18390799 ↗
L4RCTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment, Multiglandular Syndromes, Genetic Context and Co-Axis Effects
[127]
Kumarendran B, O'Reilly MW, Subramanian A et al.. “Polycystic Ovary Syndrome, Combined Oral Contraceptives, and the Risk of Dysglycemia: A Population-Based Cohort Study With a Nested Pharmacoepidemiological Case-Control Study.” Diabetes care (2021). PMID: 34649997 ↗
L2COHORTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Complications and Long-term Sequelae
[128]
Hirschberg AL. “Approach to Investigation of Hyperandrogenism in a Postmenopausal Woman.” The Journal of clinical endocrinology and metabolism (2023). PMID: 36409990 ↗
L5REVIEW_NARRATIVECited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
[129]
Joham AE, Tay CT, Laven J et al.. “Approach to the Patient: Diagnostic Challenges in the Workup for Polycystic Ovary Syndrome.” The Journal of clinical endocrinology and metabolism (2025). PMID: 39836632 ↗
L5REVIEW_NARRATIVECited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
[130]
Gibson-Helm M, Teede H, Dunaif A et al.. “Delayed Diagnosis and a Lack of Information Associated With Dissatisfaction in Women With Polycystic Ovary Syndrome.” The Journal of clinical endocrinology and metabolism (2017). PMID: 27906550 ↗
L4OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
[131]
Baillargeon JP, Diamanti-Kandarakis E, Ostlund RE et al.. “Altered D-chiro-inositol urinary clearance in women with polycystic ovary syndrome.” Diabetes care (2006). PMID: 16443877 ↗
L3OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
[132]
Glintborg D, Andersen M. “MANAGEMENT OF ENDOCRINE DISEASE: Morbidity in polycystic ovary syndrome.” European journal of endocrinology (2016). PMID: 27601016 ↗
L5REVIEW_NARRATIVECited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Severity, Staging and Risk Stratification, Prognosis, Natural History and Prevention
[133]
Subramanian A, Anand A, Adderley NJ et al.. “Increased COVID-19 infections in women with polycystic ovary syndrome: a population-based study.” European journal of endocrinology (2021). PMID: 33635829 ↗
L2OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
[134]
Vrbikova J, Hill M, Bendlova B et al.. “Incretin levels in polycystic ovary syndrome.” European journal of endocrinology (2008). PMID: 18511472 ↗
L3OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
[135]
Sathyapalan T, Atkin SL. “Recent advances in cardiovascular aspects of polycystic ovary syndrome.” European journal of endocrinology (2011). PMID: 22096112 ↗
L5REVIEW_NARRATIVECited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Complications and Long-term Sequelae
[136]
Möhlig M, Flöter A, Spranger J et al.. “Predicting impaired glucose metabolism in women with polycystic ovary syndrome by decision tree modelling.” Diabetologia (2006). PMID: 16972044 ↗
L4OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, History and Evolution of Treatment, Prognosis, Natural History and Prevention
[137]
Guo X, Cui J, Jones MR et al.. “Insulin clearance: confirmation as a highly heritable trait, and genome-wide linkage analysis.” Diabetologia (2012). PMID: 22584727 ↗
L4OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Prognosis, Natural History and Prevention
[138]
Huang P, Li Y, Kong FS et al.. “A Risk Score for Polycystic Ovary Syndrome Based on Meta-Analysis and Machine Learning of Gut Microbiota Signatures.” Reproductive sciences (Thousand Oaks, Calif.) (2026). PMID: 42321548 ↗
L2SR_OBSCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
[139]
Yu H, Peng L. “Artificial intelligence in ovarian pathophysiology and management: a systematic review and meta-analysis.” Journal of ovarian research (2026). PMID: 42092958 ↗
L2SR_OBSCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Severity, Staging and Risk Stratification, Prognosis, Natural History and Prevention
[140]
Liu T, Bo W, Cao Q et al.. “The accuracy of lipid accumulation product to predict metabolic syndrome in PCOS: a meta-analysis and comparative analysis with other indicators.” Frontiers in endocrinology (2026). PMID: 42064769 ↗
L2SR_OBSCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Prognosis, Natural History and Prevention
[141]
Rosenfield RL. “Normal and Premature Adrenarche.” Endocrine reviews (2021). PMID: 33788946 ↗
L5REVIEW_NARRATIVECited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Multiglandular Syndromes, Genetic Context and Co-Axis Effects
[142]
Patel B, Koysombat K, Mills EG et al.. “The Emerging Therapeutic Potential of Kisspeptin and Neurokinin B.” Endocrine reviews (2024). PMID: 37467734 ↗
L5REVIEW_NARRATIVECited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Special Populations, Pregnancy and Fertility
[143]
Showell MG, Mackenzie-Proctor R, Jordan V et al.. “Inositol for subfertile women with polycystic ovary syndrome.” The Cochrane database of systematic reviews (2018). PMID: 30570133 ↗
L1SR_OBSCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Special Populations, Pregnancy and Fertility
[144]
Zhang B, Mitsunami M, Peebles E et al.. “Early-life exposure to ambient temperature and polycystic ovary syndrome: a nationwide cohort study.” International journal of epidemiology (2026). PMID: 42204813 ↗
L2COHORTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
[145]
Patrick H, McAlister L, Pourtousi A et al.. “Opportunities to improve the care of individuals with polycystic ovary syndrome in Canada: Systematic review.” Canadian family physician Medecin de famille canadien (2026). PMID: 41980840 ↗
L2SR_OBSCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
[146]
Shan D, Han J, Cai Y et al.. “Reproductive Health in First-degree Relatives of Patients With Polycystic Ovary Syndrome: A Review and Meta-analysis.” The Journal of clinical endocrinology and metabolism (2022). PMID: 34453540 ↗
L2SR_OBSCited in: Severity, Staging and Risk Stratification
[147]
Jéru I, Vantyghem MC, Bismuth E et al.. “Diagnostic Challenge in PLIN1-Associated Familial Partial Lipodystrophy.” The Journal of clinical endocrinology and metabolism (2019). PMID: 31504636 ↗
L4CASE_REPORTCited in: Severity, Staging and Risk Stratification, History and Evolution of Treatment
[148]
Pasquali R, Gambineri A. “Therapy in endocrine disease: treatment of hirsutism in the polycystic ovary syndrome.” European journal of endocrinology (2013). PMID: 24272197 ↗
L5REVIEW_NARRATIVECited in: Severity, Staging and Risk Stratification
[149]
Rosenfield RL. “The Search for the Causes of Common Hyperandrogenism, 1965 to Circa 2015.” Endocrine reviews (2024). PMID: 38457123 ↗
L5REVIEW_NARRATIVECited in: Severity, Staging and Risk Stratification, History and Evolution of Treatment
[150]
Xiong T, Fraison E, Kolibianaki E et al.. “Statins for women with polycystic ovary syndrome not actively trying to conceive.” The Cochrane database of systematic reviews (2023). PMID: 37462232 ↗
L1SR_OBSCited in: Severity, Staging and Risk Stratification
[151]
Aytemiz EA, Aslan B, Kaplan NB et al.. “Phenotype-specific efficacy of letrozole versus clomiphene citrate in polycystic ovary syndrome: a prospective cohort study.” BMC women's health (2026). PMID: 41826916 ↗
L2COHORTCited in: Severity, Staging and Risk Stratification
[152]
Bashir R, Asrar M, Kamboj S et al.. “Metabolic-endocrine correlates of gut-brain axis mediators in polycystic ovary syndrome: A case-control study.” Journal of neuroendocrinology (2026). PMID: 42076786 ↗
L3CASE_CONTROLCited in: Severity, Staging and Risk Stratification
[153]
Buragohain S, Sarma I, Saikia D et al.. “Effectiveness of GLP-1 Receptor Agonists in Patients With Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis of Randomised Controlled Trials.” Cureus (2026). PMID: 42116999 ↗
L1SR_MA_RCTCited in: Severity, Staging and Risk Stratification
[154]
Parker MN, Richards CA, Brydum R et al.. “Psychiatric Diagnoses and Psychotropic Medications Among Military-Affiliated Adolescents and Young Adults With Polycystic Ovary Syndrome.” The Journal of adolescent health : official publication of the Society for Adolescent Medicine (2026). PMID: 42429714 ↗
L3OTHERCited in: Severity, Staging and Risk Stratification
[155]
Ropelato MG, Rudaz MC, Escobar ME et al.. “Acute effects of testosterone infusion on the serum luteinizing hormone profile in eumenorrheic and polycystic ovary syndrome adolescents.” The Journal of clinical endocrinology and metabolism (2009). PMID: 19567528 ↗
L1RCTCited in: Acute Management and Endocrine Emergencies
[156]
Pau CT, Keefe C, Duran J et al.. “Metformin improves glucose effectiveness, not insulin sensitivity: predicting treatment response in women with polycystic ovary syndrome in an open-label, interventional study.” The Journal of clinical endocrinology and metabolism (2014). PMID: 24606093 ↗
L4TRIAL_NONRANDOMCited in: Acute Management and Endocrine Emergencies
[157]
Costa S, Sampaio L, Berta Sousa A et al.. “Face-sparing Congenital Generalized Lipodystrophy Type 1 Associated With Nonclassical Congenital Adrenal Hyperplasia.” The Journal of clinical endocrinology and metabolism (2022). PMID: 35857714 ↗
L4CASE_REPORTCited in: Acute Management and Endocrine Emergencies
[158]
Dumesic DA, Phan JD, Leung KL et al.. “Adipose Insulin Resistance in Normal-Weight Women With Polycystic Ovary Syndrome.” The Journal of clinical endocrinology and metabolism (2019). PMID: 30649347 ↗
L2OTHERCited in: Acute Management and Endocrine Emergencies
[159]
O'Reilly MW, Kempegowda P, Walsh M et al.. “AKR1C3-Mediated Adipose Androgen Generation Drives Lipotoxicity in Women With Polycystic Ovary Syndrome.” The Journal of clinical endocrinology and metabolism (2017). PMID: 28645211 ↗
L3OTHERCited in: Acute Management and Endocrine Emergencies
[160]
Benrick A, Pillon NJ, Nilsson E et al.. “Electroacupuncture Mimics Exercise-Induced Changes in Skeletal Muscle Gene Expression in Women With Polycystic Ovary Syndrome.” The Journal of clinical endocrinology and metabolism (2020). PMID: 32232327 ↗
L3OTHERCited in: Acute Management and Endocrine Emergencies
[161]
Maliqueo M, Sir-Petermann T, Pérez V et al.. “Adrenal function during childhood and puberty in daughters of women with polycystic ovary syndrome.” The Journal of clinical endocrinology and metabolism (2009). PMID: 19567527 ↗
L3OTHERCited in: Acute Management and Endocrine Emergencies
[162]
Insenser M, Martínez-García MA, Montes R et al.. “Proteomic analysis of plasma in the polycystic ovary syndrome identifies novel markers involved in iron metabolism, acute-phase response, and inflammation.” The Journal of clinical endocrinology and metabolism (2010). PMID: 20484478 ↗
L3OTHERCited in: Acute Management and Endocrine Emergencies
[163]
Tosi F, Di Sarra D, Bonin C et al.. “Plasma levels of pentraxin-3, an inflammatory protein involved in fertility, are reduced in women with polycystic ovary syndrome.” European journal of endocrinology (2014). PMID: 24347428 ↗
L3OTHERCited in: Acute Management and Endocrine Emergencies
[164]
Berbrier DE, Huckins W, Delage SI et al.. “Ketone monoester ingestion improves endothelial function during hyperglycemia in females with polycystic ovary syndrome.” American journal of physiology. Endocrinology and metabolism (2026). PMID: 41494652 ↗
L4RCTCited in: Acute Management and Endocrine Emergencies
[165]
Rajab E, Moin ASM, Nandakumar M et al.. “Shared and divergent acute cardiovascular risk protein responses to lipid infusion in women with and without PCOS.” Diabetes, obesity & metabolism (2025). PMID: 41017577 ↗
L1RCTCited in: Acute Management and Endocrine Emergencies
[166]
Chen L, Lu J, Hu J et al.. “Unveiling the multifaceted role of adropin in various diseases (Review).” International journal of molecular medicine (2024). PMID: 39155866 ↗
L5SR_OBSCited in: Acute Management and Endocrine Emergencies
[167]
Holmskov M, Christensen J, Larsen MF et al.. “Polycystic ovary syndrome in women with bipolar affective disorder or epilepsy exposed to valproic acid: a nationwide 16-year cohort study.” International journal of bipolar disorders (2026). PMID: 41533184 ↗
L2COHORTCited in: Acute Management and Endocrine Emergencies
[168]
Gastaldon C, Whitesell Skrivankova V, Schoretsanitis G et al.. “Diagnosis of postpartum depression and associated factors in South Africa: a cohort study of 47,697 women.” Epidemiology and psychiatric sciences (2025). PMID: 40726088 ↗
L2COHORTCited in: Acute Management and Endocrine Emergencies
[169]
Verfürden ML, Schnecke V, Winning Lehmann E et al.. “Association between weight loss and reproductive outcomes among women with overweight or obesity: a cohort study using UK real-world data.” Human reproduction (Oxford, England) (2025). PMID: 40618200 ↗
L2COHORTCited in: Acute Management and Endocrine Emergencies
[170]
Yu EH, Lee HJ, Joo JK et al.. “Comparing programmed, modified natural and natural cycle frozen embryo transfer on obstetric outcomes in polycystic ovary syndrome: a national cohort study.” Journal of assisted reproduction and genetics (2025). PMID: 40531303 ↗
L2COHORTCited in: Acute Management and Endocrine Emergencies
[171]
Guo X, Yao Y, Wang T et al.. “The impact of hyperandrogenemia on pregnancy complications and outcomes in patients with PCOS: a systematic review and meta-analysis.” Hypertension in pregnancy (2024). PMID: 39004840 ↗
L1SR_OBSCited in: Acute Management and Endocrine Emergencies
[172]
Luque-Ramírez M, Alvarez-Blasco F, Botella-Carretero JI et al.. “Increased body iron stores of obese women with polycystic ovary syndrome are a consequence of insulin resistance and hyperinsulinism and are not a result of reduced menstrual losses.” Diabetes care (2007). PMID: 17536071 ↗
L4RCTCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment, Multiglandular Syndromes, Genetic Context and Co-Axis Effects
[173]
Yang M, Liu R, Li S et al.. “Zinc-α2-glycoprotein is associated with insulin resistance in humans and is regulated by hyperglycemia, hyperinsulinemia, or liraglutide administration: cross-sectional and interventional studies in normal subjects, insulin-resistant subjects, and subjects with newly diagnosed diabetes.” Diabetes care (2012). PMID: 23275352 ↗
L4RCTCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment
[174]
Glintborg D, Højlund K, Andersen M et al.. “Soluble CD36 and risk markers of insulin resistance and atherosclerosis are elevated in polycystic ovary syndrome and significantly reduced during pioglitazone treatment.” Diabetes care (2007). PMID: 18000176 ↗
L1RCTCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment
[175]
Salamun V, Jensterle M, Janez A et al.. “Liraglutide increases IVF pregnancy rates in obese PCOS women with poor response to first-line reproductive treatments: a pilot randomized study.” European journal of endocrinology (2018). PMID: 29703793 ↗
L1RCTCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment, Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Special Populations, Pregnancy and Fertility
[176]
Rittig N, Christiansen Arlien-Søborg M, Svart MV et al.. “Ketone supplementation acutely lowers androgen and glucose levels in women with polycystic ovary syndrome: a randomized clinical trial.” European journal of endocrinology (2025). PMID: 40393075 ↗
L1RCTCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment
[177]
Shang Y, Zhou H, Hu M et al.. “Effect of Diet on Insulin Resistance in Polycystic Ovary Syndrome.” The Journal of clinical endocrinology and metabolism (2020). PMID: 32621748 ↗
L1SR_OBSCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Multiglandular Syndromes, Genetic Context and Co-Axis Effects
[178]
Melin J, Forslund M, Alesi S et al.. “Metformin and Combined Oral Contraceptive Pills in the Management of Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis.” The Journal of clinical endocrinology and metabolism (2024). PMID: 37554096 ↗
L1SR_OBSCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
[179]
Chen ZJ, Shi Y, Sun Y et al.. “Fresh versus Frozen Embryos for Infertility in the Polycystic Ovary Syndrome.” The New England journal of medicine (2016). PMID: 27509101 ↗
L1RCTCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment, Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Complications and Long-term Sequelae, Special Populations, Pregnancy and Fertility
[180]
Shi Y, Sun Y, Hao C et al.. “Transfer of Fresh versus Frozen Embryos in Ovulatory Women.” The New England journal of medicine (2018). PMID: 29320646 ↗
L1RCTCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment, Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Complications and Long-term Sequelae, Special Populations, Pregnancy and Fertility
[181]
Legro RS, Barnhart HX, Schlaff WD et al.. “Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome.” The New England journal of medicine (2007). PMID: 17287476 ↗
L1RCTCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment, Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Complications and Long-term Sequelae, Special Populations, Pregnancy and Fertility
[182]
Vuong LN, Dang VQ, Ho TM et al.. “IVF Transfer of Fresh or Frozen Embryos in Women without Polycystic Ovaries.” The New England journal of medicine (2018). PMID: 29320655 ↗
L1RCTCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment, Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Special Populations, Pregnancy and Fertility
[183]
Kjerpeseth LJ, Cesta CE, Furu K et al.. “Metformin Versus Insulin and Risk of Major Congenital Malformations in Pregnancies With Type 2 Diabetes: A Nordic Register-Based Cohort Study.” Diabetes care (2023). PMID: 37343541 ↗
L2COHORTCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Special Populations, Pregnancy and Fertility
[184]
Forslund M, Melin J, Alesi S et al.. “Different kinds of oral contraceptive pills in polycystic ovary syndrome: a systematic review and meta-analysis.” European journal of endocrinology (2023). PMID: 37440702 ↗
L1SR_OBSCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
[185]
Smedegaard S, Rittig N, Ovesen PG et al.. “Once-daily supplementation with pre-meal whey protein lowers breakfast postprandial glucose levels in women with GDM throughout the third trimester: a randomised, controlled, clinical trial.” Diabetologia (2025). PMID: 41203981 ↗
L1RCTCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment, Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Special Populations, Pregnancy and Fertility
[186]
Palomba S, Falbo A, Giallauria F et al.. “Effects of metformin with or without supplementation with folate on homocysteine levels and vascular endothelium of women with polycystic ovary syndrome.” Diabetes care (2009). PMID: 19933994 ↗
L2OTHERCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae
[187]
Pasquali R, Gambineri A. “Insulin-sensitizing agents in polycystic ovary syndrome.” European journal of endocrinology (2006). PMID: 16728533 ↗
L5REVIEW_NARRATIVECited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Special Populations, Pregnancy and Fertility
[188]
Bult MJ, van Dalen T, Muller AF. “Surgical treatment of obesity.” European journal of endocrinology (2008). PMID: 18230819 ↗
L5REVIEW_NARRATIVECited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae
[189]
Aminian M, Hajshafiha M, Heidari M et al.. “Effect of two types of time-restricted eating on glycemic, lipid indices, and weight in women with polycystic ovary syndrome: a randomized controlled trial.” European journal of nutrition (2026). PMID: 42371138 ↗
L1RCTCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment
[190]
Mu L, Shen Y, Wang G et al.. “Dihydroartemisinin for the treatment of polycystic ovary syndrome: study protocol for a multi-centre placebo-controlled randomised clinical trial.” BMJ open (2026). PMID: 42320967 ↗
L5TRIAL_NONRANDOMCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
[191]
Sharifi M, Dehghani MJ, Karimi MA et al.. “Serum anti-Müllerian hormone levels in women following bariatric surgery: insights from a systematic review and meta-analysis.” BMC endocrine disorders (2026). PMID: 42401855 ↗
L2SR_OBSCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Special Populations, Pregnancy and Fertility
[192]
Gautam R, Maan P, Arora A et al.. “Yoga as a complementary intervention for polycystic ovary Syndrome management: a systematic review.” Frontiers in reproductive health (2026). PMID: 42318079 ↗
L2SR_OBSCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Prognosis, Natural History and Prevention
[193]
Chen Y, Wang G, Chen J et al.. “Genetic and Epigenetic Landscape for Drug Development in Polycystic Ovary Syndrome.” Endocrine reviews (2024). PMID: 38298137 ↗
L5REVIEW_NARRATIVECited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment
[194]
Mueller JW, Gilligan LC, Idkowiak J et al.. “The Regulation of Steroid Action by Sulfation and Desulfation.” Endocrine reviews (2015). PMID: 26213785 ↗
L5REVIEW_NARRATIVECited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
[195]
Palomba S, Falbo A, Zullo F et al.. “Evidence-based and potential benefits of metformin in the polycystic ovary syndrome: a comprehensive review.” Endocrine reviews (2008). PMID: 19056992 ↗
L5REVIEW_NARRATIVECited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae, Prognosis, Natural History and Prevention, Special Populations, Pregnancy and Fertility
[196]
Morley LC, Tang T, Yasmin E et al.. “Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility.” The Cochrane database of systematic reviews (2017). PMID: 29183107 ↗
L1SR_OBSCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Complications and Long-term Sequelae, Special Populations, Pregnancy and Fertility
[197]
Shawish MI, Bagheri B, Musini VM et al.. “Effect of atorvastatin on testosterone levels.” The Cochrane database of systematic reviews (2021). PMID: 33482034 ↗
L1SR_OBSCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
[198]
Xie M, Zhou S, Wu J et al.. “Determinants of dropout from lifestyle interventions for overweight polycystic ovary syndrome: An exploratory analysis of randomized controlled trial.” PloS one (2026). PMID: 42361044 ↗
L2RCTCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
[199]
Wang J, Zhou W, Song Z et al.. “Does the Risk of Embryo Abnormality Increase in PCOS Women? A Secondary Analysis of a Multicenter, Randomized Controlled Trial.” The Journal of clinical endocrinology and metabolism (2023). PMID: 36546342 ↗
L2RCTCited in: History and Evolution of Treatment
[200]
Marchesan LB, da Silva TR, Spritzer PM. “Topiramate Added to Metformin for Obesity Control in Women With Polycystic Ovary Syndrome.” The Journal of clinical endocrinology and metabolism (2025). PMID: 39271474 ↗
L1RCTCited in: History and Evolution of Treatment
[201]
Mantzoros CS, Dunaif A, Flier JS. “Leptin concentrations in the polycystic ovary syndrome.” The Journal of clinical endocrinology and metabolism (1997). PMID: 9177364 ↗
L3RCTCited in: History and Evolution of Treatment
[202]
Belan M, Giguère-Johnson M, Carranza-Mamane B et al.. “Lifestyle intervention before and during fertility treatment in women with obesity or with overweight and PCOS-a RCT.” The Journal of clinical endocrinology and metabolism (2026). PMID: 41402995 ↗
L1RCTCited in: History and Evolution of Treatment
[203]
Fraser GL, Obermayer-Pietsch B, Laven J et al.. “Randomized Controlled Trial of Neurokinin 3 Receptor Antagonist Fezolinetant for Treatment of Polycystic Ovary Syndrome.” The Journal of clinical endocrinology and metabolism (2021). PMID: 34000049 ↗
L1RCTCited in: History and Evolution of Treatment
[204]
McDonnell T, Anthony AV, Clarke G et al.. “Hepatic metabolism of 11-oxygenated androgens in humans: an integrated in vivo and ex vivo approach.” European journal of endocrinology (2025). PMID: 40795393 ↗
L4RCTCited in: History and Evolution of Treatment
[205]
Kelly CJ, Gordon D. “The effect of metformin on hirsutism in polycystic ovary syndrome.” European journal of endocrinology (2002). PMID: 12153743 ↗
L1RCTCited in: History and Evolution of Treatment
[206]
Gashaw I, Reif S, Wiesinger H et al.. “Novel aldo-keto reductase 1C3 inhibitor affects androgen metabolism but not ovarian function in healthy women: a phase 1 study.” European journal of endocrinology (2023). PMID: 37306288 ↗
L4RCTCited in: History and Evolution of Treatment
[207]
Donà G, Sabbadin C, Fiore C et al.. “Inositol administration reduces oxidative stress in erythrocytes of patients with polycystic ovary syndrome.” European journal of endocrinology (2012). PMID: 22223702 ↗
L1RCTCited in: History and Evolution of Treatment
[208]
Oberg E, Lundell C, Blomberg L et al.. “Psychological well-being and personality in relation to weight loss following behavioral modification intervention in obese women with polycystic ovary syndrome: a randomized controlled trial.” European journal of endocrinology (2020). PMID: 32503005 ↗
L1RCTCited in: History and Evolution of Treatment
[209]
Nestler JE, Jakubowicz DJ, Reamer P et al.. “Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome.” The New England journal of medicine (1999). PMID: 10219066 ↗
L1RCTCited in: History and Evolution of Treatment
[210]
Nestler JE, Jakubowicz DJ. “Decreases in ovarian cytochrome P450c17 alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome.” The New England journal of medicine (1996). PMID: 8687515 ↗
L4RCTCited in: History and Evolution of Treatment
[211]
Dennedy MC, Smith D, O'Shea D et al.. “Investigation of patients with atypical or severe hyperandrogenaemia including androgen-secreting ovarian teratoma.” European journal of endocrinology (2009). PMID: 19906851 ↗
L5CASE_REPORTCited in: History and Evolution of Treatment, Prognosis, Natural History and Prevention
[212]
Xita N, Tsatsoulis A. “Review: fetal programming of polycystic ovary syndrome by androgen excess: evidence from experimental, clinical, and genetic association studies.” The Journal of clinical endocrinology and metabolism (2006). PMID: 16522691 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
[213]
Ramachandran A, Snehalatha C, Satyavani K et al.. “Type 2 diabetes in Asian-Indian urban children.” Diabetes care (2003). PMID: 12663567 ↗
L4OTHERCited in: History and Evolution of Treatment
[214]
Ehrmann DA, Barnes RB, Rosenfield RL et al.. “Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome.” Diabetes care (1999). PMID: 10333916 ↗
L4OTHERCited in: History and Evolution of Treatment
[215]
Farquhar C, Lilford RJ, Marjoribanks J et al.. “Laparoscopic "drilling" by diathermy or laser for ovulation induction in anovulatory polycystic ovary syndrome.” The Cochrane database of systematic reviews (2005). PMID: 16034856 ↗
L1SR_OBSCited in: History and Evolution of Treatment
[216]
Farquhar C, Vandekerckhove P, Lilford R. “Laparoscopic "drilling" by diathermy or laser for ovulation induction in anovulatory polycystic ovary syndrome.” The Cochrane database of systematic reviews (2001). PMID: 11687100 ↗
L1SR_OBSCited in: History and Evolution of Treatment
[217]
Farquhar C, Lilford RJ, Marjoribanks J et al.. “Laparoscopic 'drilling' by diathermy or laser for ovulation induction in anovulatory polycystic ovary syndrome.” The Cochrane database of systematic reviews (2007). PMID: 17636653 ↗
L1SR_OBSCited in: History and Evolution of Treatment
[218]
Farquhar C, Vandekerckhove P, Arnot M et al.. “Laparoscopic "drilling" by diathermy or laser for ovulation induction in anovulatory polycystic ovary syndrome.” The Cochrane database of systematic reviews (2000). PMID: 10796746 ↗
L1SR_OBSCited in: History and Evolution of Treatment
[219]
Farquhar C, Brown J, Marjoribanks J. “Laparoscopic drilling by diathermy or laser for ovulation induction in anovulatory polycystic ovary syndrome.” The Cochrane database of systematic reviews (2012). PMID: 22696324 ↗
L1SR_OBSCited in: History and Evolution of Treatment
[220]
Hughes E, Collins J, Vandekerckhove P. “WITHDRAWN: Ovulation induction with urinary follicle stimulating hormone versus human menopausal gonadotropin for clomiphene-resistant polycystic ovary syndrome.” The Cochrane database of systematic reviews (1996). PMID: 17636586 ↗
L1SR_OBSCited in: History and Evolution of Treatment
[221]
Nugent D, Vanderkerchove P, Hughes E et al.. “WITHDRAWN: Gonadotrophin therapy for ovulation induction in subfertility associated with polycystic ovary syndrome.” The Cochrane database of systematic reviews (2015). PMID: 26299777 ↗
L1SR_OBSCited in: History and Evolution of Treatment
[222]
Nahuis M, Bayram N, Van der Veen F et al.. “WITHDRAWN: Recombinant FSH versus urinary gonadotrophins or recombinant FSH for ovulation induction in subfertility associated with polycystic ovary syndrome.” The Cochrane database of systematic reviews (2015). PMID: 26299778 ↗
L1SR_OBSCited in: History and Evolution of Treatment
[223]
Yang Z, Xu Y, Du H et al.. “Short-Term Combined Treatment With Tirzepatide and Metformin for Overweight/Obese Chinese Women With Polycystic Ovary Syndrome: A Prospective, Open-Label, Randomised Controlled Trial.” Diabetes, obesity & metabolism (2026). PMID: 42236268 ↗
L1RCTCited in: History and Evolution of Treatment, Special Populations, Pregnancy and Fertility
[224]
Ren J, Chen H, Zhang L et al.. “Effects of Tai Chi combined with dietary intervention on health-promoting lifestyle and metabolic and reproductive outcomes in female college students with polycystic ovary syndrome: a randomized controlled trial.” Frontiers in endocrinology (2026). PMID: 42147112 ↗
L1RCTCited in: History and Evolution of Treatment
[225]
Corapi S, Runchey MC, Lyons J et al.. “Time-restricted eating for body weight management in women with polycystic ovary syndrome: a randomized controlled trial.” Nature medicine (2026). PMID: 41896647 ↗
L1RCTCited in: History and Evolution of Treatment
[226]
Samarasinghe SNS, Abbara A, Ortega PM et al.. “Ovulatory Recovery following weight loss in women with polycystic ovary syndrome and obesity: a post hoc analysis of the BAMBINI randomised controlled trial.” Human reproduction (Oxford, England) (2026). PMID: 41808368 ↗
L2RCTCited in: History and Evolution of Treatment
[227]
Hosseinabad MF, Masnavi E, Eslamnik PA et al.. “Adjunctive melatonin and sildenafil, enhances antioxidant defense in metformin-treated polycystic ovary syndrome patients: A randomized study.” Journal of gynecology obstetrics and human reproduction (2026). PMID: 41881108 ↗
L1RCTCited in: History and Evolution of Treatment
[228]
Behroozilak T, Farshadfar M, Jahangard S. “Effect of Probiotic Supplementation on Reproductive Outcomes of Women With Polycystic Ovary Syndrome Who Are Candidates for Intrauterine Insemination: A Randomized, Double-Blind, Placebo-Controlled Trial.” Endocrinology, diabetes & metabolism (2026). PMID: 41776814 ↗
L1RCTCited in: History and Evolution of Treatment
[229]
Taheri H, Seydi F, Jalali-Mashayekhi F et al.. “Effects of Arctium lappa L. Root Powder on Some Markers of Oxidative Stress and Inflammation in Women with Polycystic Ovary Syndrome: A Randomized, Double-Blind Controlled Clinical Trial Study.” JBRA assisted reproduction (2026). PMID: 41757842 ↗
L1RCTCited in: History and Evolution of Treatment
[230]
Liu Y, Yu H, Peng J et al.. “Construction and validation of a machine learning model for predicting early pregnancy in patients with polycystic ovary syndrome: a retrospective cohort study.” Journal of ovarian research (2026). PMID: 42415121 ↗
L2COHORTCited in: History and Evolution of Treatment, Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Special Populations, Pregnancy and Fertility
[231]
Shao C, Li W, Liang J. “Effects of acupuncture on improving hormonal and metabolic biochemical characteristics in polycystic ovary syndrome.” African journal of reproductive health (2026). PMID: 41841598 ↗
L1RCTCited in: History and Evolution of Treatment
[232]
Melin J, Forslund M, Alesi S et al.. “The impact of metformin with or without lifestyle modification versus placebo on polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials.” European journal of endocrinology (2023). PMID: 37536294 ↗
L1SR_MA_RCTCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects
[233]
Fitz V, Graca S, Mahalingaiah S et al.. “Inositol for Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis to Inform the 2023 Update of the International Evidence-based PCOS Guidelines.” The Journal of clinical endocrinology and metabolism (2024). PMID: 38163998 ↗
L1SR_OBSCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects
[234]
Hutchison SK, Teede HJ, Rachoń D et al.. “Effect of exercise training on insulin sensitivity, mitochondria and computed tomography muscle attenuation in overweight women with and without polycystic ovary syndrome.” Diabetologia (2012). PMID: 22246378 ↗
L2RCTCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects
[235]
Wojciechowski P, Lipowska A, Rys P et al.. “Impact of FTO genotypes on BMI and weight in polycystic ovary syndrome: a systematic review and meta-analysis.” Diabetologia (2012). PMID: 22801903 ↗
L3SR_OBSCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects
[236]
Sun Z, Zhang R, Tian X et al.. “Efficacy of probiotic and synbiotic supplementation on metabolic and endocrine parameters in polycystic ovary syndrome: a meta-analysis of randomized controlled trials.” BMC endocrine disorders (2026). PMID: 42420973 ↗
L1SR_MA_RCTCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects
[237]
Liu Q, Tang B, Zhu Z et al.. “A genome-wide cross-trait analysis identifies shared loci and causal relationships of type 2 diabetes and glycaemic traits with polycystic ovary syndrome.” Diabetologia (2022). PMID: 35771237 ↗
L2OTHERCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Complications and Long-term Sequelae, Prognosis, Natural History and Prevention
[238]
Moreira MV, Guerra-Carvalho B, Vale-Fernandes E et al.. “Metabolic profiling of human follicular fluid to unravel the pathways involved in polycystic ovary syndrome - a systematic review.” Reviews in endocrine & metabolic disorders (2026). PMID: 42406284 ↗
L3SR_OBSCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects
[239]
Rajendran R, Abdul Khader M, Shivanna P et al.. “Screening for endometrial hyperplasia and endometrial cancer in premenopausal women with polycystic ovary syndrome: a systematic review protocol.” BMJ open (2026). PMID: 42379723 ↗
L5SR_OBSCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Prognosis, Natural History and Prevention
[240]
Rosenfield RL, Ehrmann DA. “The Pathogenesis of Polycystic Ovary Syndrome (PCOS): The Hypothesis of PCOS as Functional Ovarian Hyperandrogenism Revisited.” Endocrine reviews (2016). PMID: 27459230 ↗
L5REVIEW_NARRATIVECited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Prognosis, Natural History and Prevention
[241]
Riestenberg C, Jagasia A, Markovic D et al.. “Health Care-Related Economic Burden of Polycystic Ovary Syndrome in the United States: Pregnancy-Related and Long-Term Health Consequences.” The Journal of clinical endocrinology and metabolism (2022). PMID: 34546364 ↗
L2SR_OBSCited in: Complications and Long-term Sequelae, Special Populations, Pregnancy and Fertility
[242]
Domecq JP, Prutsky G, Mullan RJ et al.. “Adverse effects of the common treatments for polycystic ovary syndrome: a systematic review and meta-analysis.” The Journal of clinical endocrinology and metabolism (2013). PMID: 24092830 ↗
L2SR_OBSCited in: Complications and Long-term Sequelae
[243]
Glintborg D, Ollila MM, Koskenkari N et al.. “Increased prospective cardiovascular disease risk in 127 517 Nordic women with polycystic ovary syndrome: a national cohort study.” European journal of endocrinology (2026). PMID: 41439462 ↗
L2COHORTCited in: Complications and Long-term Sequelae
[244]
Wang ET, Cirillo PM, Vittinghoff E et al.. “Menstrual irregularity and cardiovascular mortality.” The Journal of clinical endocrinology and metabolism (2010). PMID: 20980429 ↗
L2OTHERCited in: Complications and Long-term Sequelae
[245]
Macut D, Božić-Antić I, Bjekić-Macut J et al.. “MANAGEMENT OF ENDOCRINE DISEASE: Polycystic ovary syndrome and nonalcoholic fatty liver disease.” European journal of endocrinology (2017). PMID: 28694246 ↗
L5REVIEW_NARRATIVECited in: Complications and Long-term Sequelae
[246]
Sharpe A, Morley LC, Tang T et al.. “Metformin for ovulation induction (excluding gonadotrophins) in women with polycystic ovary syndrome.” The Cochrane database of systematic reviews (2019). PMID: 31845767 ↗
L1SR_OBSCited in: Complications and Long-term Sequelae
[247]
Bordewijk EM, Ng KYB, Rakic L et al.. “Laparoscopic ovarian drilling for ovulation induction in women with anovulatory polycystic ovary syndrome.” The Cochrane database of systematic reviews (2020). PMID: 32048270 ↗
L1SR_OBSCited in: Complications and Long-term Sequelae
[248]
Wang F, Fu L, Zhou T et al.. “Gestational lipid profile partially mediates adverse obstetric outcomes associated with polycystic ovary syndrome: a multicentre cohort study in China.” Lipids in health and disease (2026). PMID: 42402586 ↗
L3COHORTCited in: Complications and Long-term Sequelae, Special Populations, Pregnancy and Fertility
[249]
Tang M, Deng X, Liu S et al.. “Polyendocrine metabolic ovarian syndrome and cardiometabolic profile in offspring: a propensity score matched cohort study.” Reproductive biomedicine online (2026). PMID: 42364288 ↗
L3COHORTCited in: Complications and Long-term Sequelae
[250]
Varma R, Ilelaboye A, Ugwuja F et al.. “Hormonal therapy and cardiovascular risk in polycystic ovary syndrome: a propensity-matched cohort study.” Proceedings (Baylor University. Medical Center) (2026). PMID: 42269075 ↗
L3COHORTCited in: Complications and Long-term Sequelae
[251]
Salley KE, Wickham EP, Cheang KI et al.. “Glucose intolerance in polycystic ovary syndrome--a position statement of the Androgen Excess Society.” The Journal of clinical endocrinology and metabolism (2007). PMID: 18056778 ↗
L5SR_OBSCited in: Prognosis, Natural History and Prevention
[252]
Domecq JP, Prutsky G, Mullan RJ et al.. “Lifestyle modification programs in polycystic ovary syndrome: systematic review and meta-analysis.” The Journal of clinical endocrinology and metabolism (2013). PMID: 24092832 ↗
L1SR_OBSCited in: Prognosis, Natural History and Prevention, Special Populations, Pregnancy and Fertility
[253]
van der Ham K, Moolhuijsen LME, Brewer K et al.. “Clustering Identifies Subtypes With Different Phenotypic Characteristics in Women With Polycystic Ovary Syndrome.” The Journal of clinical endocrinology and metabolism (2024). PMID: 38753423 ↗
L4OTHERCited in: Prognosis, Natural History and Prevention
[254]
Dunaif A, Fauser BC. “Renaming PCOS--a two-state solution.” The Journal of clinical endocrinology and metabolism (2013). PMID: 24009134 ↗
L5OTHERCited in: Prognosis, Natural History and Prevention
[255]
Rosenfield RL. “Clinical review: Identifying children at risk for polycystic ovary syndrome.” The Journal of clinical endocrinology and metabolism (2006). PMID: 17179197 ↗
L5REVIEW_NARRATIVECited in: Prognosis, Natural History and Prevention
[256]
Pasquali R, Diamanti-Kandarakis E, Gambineri A. “MANAGEMENT OF ENDOCRINE DISEASE: Secondary polycystic ovary syndrome: theoretical and practical aspects.” European journal of endocrinology (2016). PMID: 27170519 ↗
L5REVIEW_NARRATIVECited in: Prognosis, Natural History and Prevention
[257]
Lecot-Connan T, Bachelot G, Donadille B et al.. “Using machine learning to discriminate non-classical 21-hydroxylase deficiency from polycystic ovary syndrome: an external validation study.” European journal of endocrinology (2026). PMID: 42411601 ↗
L4OTHERCited in: Prognosis, Natural History and Prevention
[258]
Luque-Ramírez M, Alpañés M, Sanchón R et al.. “Referral bias in female functional hyperandrogenism and polycystic ovary syndrome.” European journal of endocrinology (2015). PMID: 26243032 ↗
L4OTHERCited in: Prognosis, Natural History and Prevention
[259]
Muscogiuri G, Mitri J, Mathieu C et al.. “Mechanisms in endocrinology: vitamin D as a potential contributor in endocrine health and disease.” European journal of endocrinology (2014). PMID: 24872497 ↗
L5REVIEW_NARRATIVECited in: Prognosis, Natural History and Prevention
[260]
Livadas S, Yildiz BO, Mastorakos G et al.. “European survey of diagnosis and management of the polycystic ovary syndrome: full report on the ESE PCOS Special Interest Group's 2023 Questionnaire.” European journal of endocrinology (2024). PMID: 39099229 ↗
L4OTHERCited in: Prognosis, Natural History and Prevention
[261]
Gui Z, Lin H, Wang C et al.. “Association between bisphenol exposure and polycystic ovary syndrome risk: an integrated systematic review and meta-analysis.” Frontiers in endocrinology (2026). PMID: 42369063 ↗
L3SR_OBSCited in: Prognosis, Natural History and Prevention
[262]
Hu S, Shen Q, Li Z et al.. “Ranking exercise interventions by their effectiveness in the management of polycystic ovary syndrome: a systematic review and network meta-analysis.” Reproductive biology and endocrinology : RB&E (2026). PMID: 42050523 ↗
L1SR_OBSCited in: Prognosis, Natural History and Prevention
[263]
Youssef MA, Mourad S. “Volume expanders for the prevention of ovarian hyperstimulation syndrome.” The Cochrane database of systematic reviews (2016). PMID: 27577848 ↗
L1SR_OBSCited in: Prognosis, Natural History and Prevention
[264]
Helseth R, Vanky E, Salvesen O et al.. “Gestational diabetes mellitus among Norwegian women with polycystic ovary syndrome: prevalence and risk factors according to the WHO and the modified IADPSG criteria.” European journal of endocrinology (2013). PMID: 23636445 ↗
L2RCTCited in: Special Populations, Pregnancy and Fertility
[265]
Ott J, Wattar L, Kurz C et al.. “Parameters for calcium metabolism in women with polycystic ovary syndrome who undergo clomiphene citrate stimulation: a prospective cohort study.” European journal of endocrinology (2012). PMID: 22330149 ↗
L2COHORTCited in: Special Populations, Pregnancy and Fertility
[266]
Palomba S. “Aromatase inhibitors for ovulation induction.” The Journal of clinical endocrinology and metabolism (2015). PMID: 25710566 ↗
L5REVIEW_NARRATIVECited in: Special Populations, Pregnancy and Fertility
[267]
Paalanne M, Vääräsmäki M, Mustaniemi S et al.. “Clinical and biochemical signs of polycystic ovary syndrome in young women born preterm.” European journal of endocrinology (2021). PMID: 34081616 ↗
L2OTHERCited in: Special Populations, Pregnancy and Fertility
[268]
Vryonidou A, Paschou SA, Muscogiuri G et al.. “MECHANISMS IN ENDOCRINOLOGY: Metabolic syndrome through the female life cycle.” European journal of endocrinology (2015). PMID: 26034072 ↗
L5REVIEW_NARRATIVECited in: Special Populations, Pregnancy and Fertility
[269]
Shi Z, Li F, Gao T et al.. “Investigation of trends, hot spots and effective therapies for pregnancy outcomes in polycystic ovary syndrome: a bibliometric analysis.” Frontiers in medicine (2026). PMID: 42221129 ↗
L5SR_OBSCited in: Special Populations, Pregnancy and Fertility
[270]
Clark KL, George JW, Przygrodzka E et al.. “Hippo Signaling in the Ovary: Emerging Roles in Development, Fertility, and Disease.” Endocrine reviews (2022). PMID: 35596657 ↗
L5REVIEW_NARRATIVECited in: Special Populations, Pregnancy and Fertility
[271]
Xu H, Li J, Yin SQ et al.. “Impact of concordance between basal LH/FSH ratio and testosterone levels on pregnancy outcomes in patients with PCOS undergoing IVF-ET cycle: a retrospective cohort study.” Journal of endocrinological investigation (2026). PMID: 42287529 ↗
L2COHORTCited in: Special Populations, Pregnancy and Fertility